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Neuroblastoma 
 
Neuroblastoma (NB) is the most common extra-cranial solid tumour in childhood [1] and it may 
be considered a malignant manifestation of aberrant sympathetic nervous system development 
(Fig 1). 
 
Fig 1. Development of the sympathoadrenal lineage of the neural crest (Cheung and Dyer. Nat Rev Cancer 2015) 
 
NB is the primary cause of death from paediatric cancer for children between the age of 1 and 5 
years; roughly, it represents 6% of all paediatric tumours and accounts for approximately 15% 
of all paediatric cancer mortality. The median age at the time of diagnosis is between 18 and 22 
mouths and 50% of the patients present a high-risk of metastatic tumour at the time of diagnosis 
[2]. 
There is a familial and a sporadic form of NB and both are defined by specific genetic mutations. 
The first is very rare (<2% of all NBs) and the major predisposition mutation identified in familial 
NB was in PHOX2B, a gene playing a critical role in the development of neural crest derived 
autonomic neurons [3]. Another common lesion associated with familial NB is in the ALK 
receptor tyrosine kinase gene [4]. ALK is expressed in the developing sympathoadrenal lineage 
of the neural crest, and it may regulate the balance between proliferation and differentiation [5]. 
While mutations of PHOX2B is relatively rare in sporadic NB, approximately 6–10% of NBs 
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carry somatic ALK activating mutations, and an additional 3–4% carry high level ALK gene 
amplifications [6]. However, the most common focal genetic lesion in sporadic NB is the 
amplification of MYCN, which occurs in approximately 22% of tumours and it is associated with 
poor outcome [7]. MYCN amplification or over-expression has been described in several other 
cancers that originate from tissues where MYCN is normally expressed and include 
retinoblastoma, Wilm’s tumor, rhabdomyosarcoma, medulloblastoma, glioblastoma, and small 
cell lung cancer [8] (Fig 1). 
Others important markers used to diagnose high-risk NB include ATRX mutations, but ATRX 
alterations alone are not sufficient to promote tumorigenesis, ploidy, chromosomes abnormalities 
and aberrant expression of tyrosine kinases receptors (Table 1) [2]. 
 
 
 
High-risk NB 
GENE FUNCTION 
 
ALK 
ALK cooperates with MYCN to drive malignancy, as activation of ALK 
results in increased expression of MYCN by elevating activity of the 
MYCN promoter. 
 
 
ATRX 
ATRX encodes a SWI/SNF chromatin-remodelling ATP-dependent 
helicase, suggesting ATRX involvement in various developmental 
processes. However, ATRX mutations alone are not sufficient to promote 
tumorigenesis. 
1p36.3 Deletion of 1p correlates with metastatic diseases. 
17q 
Gain of distal 17q is recurring feature of NB and primary tumours. 17q 
gain is itself a powerful independent predictor of poor survival 
 
 
TrkB 
Coexpressed at high levels with its ligand, BDNF, in unfavorable tumours, 
especially those with MYCN amplification. Activation of the TrkB–BDNF 
autocrine pathway can lead to invasion, metastasis, 
angiogenesis and drug resistance 
MYCN 
Mycn amplification occurs in 25%-33% of the cases and correlates with a 
greatly increased risk of fatal outcome. 
 
Tab.1 Established characteristics for high-risk NB patients. 
 
 
International Neuroblastoma Staging System (INSS), first published in 1988, used the extent of 
the initial surgical procedure to define the stage of the patient. Small localized tumours that were 
completely resected were considered Stage I lesions. Stage II tumours were small, may or may 
not have had lymphonode involvement, but could not be completely resected. Stage III lesions 
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were large tumours that crossed the anatomical midline of the patient and could not be completely 
resected. Lastly, Stage IV and IVS metastatic tumours were differentiated by the fact that IVS 
patients were <1 year of age with metastatic disease located in liver, skin and less than 10% of 
the bone marrow [9]. Most infants, with IVS metastatic disease, can be cured with moderate- 
intensity chemotherapy, and some patients with a special pattern of metastasis have a high 
likelihood of undergoing spontaneous regression without chemotherapy. Several possible 
mechanisms are proposed to support spontaneous regression in NBs: (i) neurotrophin 
deprivation, (ii) loss of telomerase activity, (iii) humoral or cellular immunity and (iv) alterations 
in epigenetic regulation and possibly other mechanisms, but the exact mechanisms responsible 
for spontaneous regression (and differentiation) are uncertain [10] [11]. 
Although the International NB Staging System (INSS) is currently used, a new International 
Neuroblastoma Risk Group (INRG) Staging System was recently proposed classifying NB 
patients into 16 risk groups on the assessment of 13 potential biological prognostic factors [12]. 
According to INRG, risk in NB is classified as low, intermediate, or high. Although low- and 
intermediate-risk patients generally have a favourable outcome (80%–95% event-free survival 
rate), high-risk patients have, 50% event-free survival rate, and there is also a subset of “ultra- 
high” risk patients who do not respond to therapy [13]. The biological hallmark of NB is the 
complexity of the genetic abnormalities acquired by the tumour cells, and some of these 
abnormalities are powerful prognostic high-risk NB markers. 
 
MYCN and p53 
 
MYCN belongs to a family that includes MYCL (L-Myc) and MYCN (N-Myc) [14] [15] [16]. 
While the role of L-Myc is less well understood, N-Myc expression is tissue-restricted, and N- 
Myc could substitute for c-Myc in murine development [17] [18]. It is crucial to understand that 
concentration of both c-MYC and MYCN proteins is finely adjusted allowing them to perform 
their normal functions [19]. While c-Myc is expressed in all proliferating tissues in the adult, 
MYCN expression in humans and mice is restricted to certain tissues in the developing embryo 
and is very low or absent in adult tissues [20] [21]. 
Structurally, c-Myc and MYCN proteins are very similar and both heterodimerize with MAX 
protein to mediates many of their functions. Myc–Max complexes bind gene promoters by 
recognizing a DNA sequence, called E-box; MYCN preferentially binds E-box CATGTG as well 
as the classic CACGTG. Moreover, under N-Myc–amplified conditions such as in NB, MYCN 
becomes less specific and can bind additional E-box motifs including CATTTG, CATCTG, and 
- 7 - 
 
CAACTG [22]. This in turn activates the transcription of downstream genes involved in diverse 
cellular functions, specifically in NB it can activate transcription of genes involved in metastasis, 
survival, proliferation, pluripotency, self-renewal, and angiogenesis and can suppress expression 
of genes that promote differentiation, cell cycle arrest, immune surveillance, and genes that 
antagonize metastasis and angiogenesis [23] (Fig. 2). 
 
 
 
 
Fig 2. MYCN plays multiple roles in malignancy and maintenance of stem-like state (Huang M. et al. Cold Spring Harb 
Perspect Med 2013). 
 
Early studies found that several c-Myc target genes were expressed in some NB cell lines with 
MYCN amplification: significant overlap between c-Myc and MYCN-regulated gene sets had 
been reported [24] [25]. By contrast, MYCN expression inversely correlates with that of c-Myc 
indeed, in MYCN amplified NB cell lines, c-Myc mRNA transcription is repressed by the high 
levels of MYCN protein [24]. 
p53 is a tumour suppressor gene that is induced and activated by a variety of potentially 
tumorigenic stresses, including inappropriate oncogene signalling and DNA damage. p53 is a 
direct target gene of c-MYC because its promoter contains a non-canonical E-box (CATGTG) 
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located upstream of the transcription initiation site and it is recognized by MYC-MAX 
heterodimers [26]. Recently, it was demonstrated that p53 is also a direct transcriptional target 
of MYCN and that p53 accumulation in NB correlates with MYCN amplification [27]. p53, often 
referred to as “guardian of the genome”, is mutated in up to 60% of many human malignancies, 
but in NB it is mutated only in 2% of the cases at the time of diagnosis [28]. Normally, p53 
function is controlled by a complex network of regulators including p14ARF, mouse double minute 
(MDM)2, and MDM4 [29]. In particular, MDM2 binds p53 and blocks its transcription and 
nuclear export, and mediates p53 degradation because MDM2 has an E3 ubiquitin ligase activity 
responsible for p53 ubiquitination [30]. 
 
 
 
 
Fig.3 – Autoregulatory feedback loop of inhibition of p53 by MDM2. (Annu Rev Pharmacol Toxicol, 2009) 
 
 
The activation of mammalian ATM promotes p53 responses by stimulating the rapid degradation 
of both MDM2 and MDM4 through C-terminal phosphorylation of both proteins [31]. The 
restoration of p53 function induces the expression of target genes such as p21 (CDKN1A), which 
leads to G1 cell-cycle arrest [32]. Moreover, DNA single strand breaks induce ATR activation 
which phosphorylates Chk1, leading to G2 cycle arrest [33]. It was demonstrated that both cell 
cycle arrest and senescence contribute to blocking tumorigenesis [34] and promote the expression 
of ligands for NK cell-activating receptors [35] [36]. 
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The human MDM2 protein, the main negative controller of p53 function (Fig. 3), is another 
oncogene that is amplified in a variety of human cancers, including NB. Interestingly, both 
MDM2 and p53 are regulated by MYCN. Moreover, MDM2 also plays p53-independent roles in 
oncogenesis regulating MYCN mRNA stabilization [37] [38]. 
 
Neuroblastoma Immune Escape 
 
Tumour growth is facilitated by cancer cell-driven immunosuppressive mechanisms. In the last 
10 years many studies have contributed to elucidate the immune evasion mechanisms adopted by 
NB cells to escape the control of the host immune system. These studies have highlighted: 
• the release of soluble molecules suppressing anti-tumour immune reactivity, such as the 
stress inducible NKG2D ligand MICA and the HLA class Ib molecule HLA-G [39]; 
• the decreased or absent expression of surface ligands for various natural killer (NK) cell- 
activating receptors, including NCRs, NKG2D and DNAM-1. In particular, defects in the 
expression of few components of the HLA class I related antigen processing machinery 
(APM) [40]; 
• the production of suppressive factors e.g. TGF-beta and IL-10, which may prevent expansion 
and activation of tumour-infiltrating lymphocytes reducing the expression of NKp30 and 
NKG2D receptor [41]; 
• the decreased expression of costimulatory molecules such as CD40, CD80, CD86, OX40L 
and 4-1BB-L, but not PD-L1and B7H2 in primary NB tumours [42]; 
• 4Ig-B7-H3 molecules expressed at the NB cell surface can exert a protective role from NK- 
mediated lysis by interacting with a still undefined inhibitory receptor expressed on NK cells 
[43]. 
The main effector cells of the immune system involved in tumour cell recognition are: (i) CD8+ 
T cells, which specifically recognize through their T cell-receptor (TCR) peptides presented by 
antigen presenting cells (APC) in the context of MHC class I molecules and mediate cytotoxic 
functions; (ii) NK cells, innate effectors, which exert their cytotoxic activity through a diverse 
repertoire of activating and inhibiting receptors that recognize specific ligands on the surface of 
the target cells; (iii) CD4+ T lymphocytes and macrophages are other important players of anti- 
tumour immune responses, mainly through the production of cytokines and inflammatory 
mediators. Defects in HLA class I and APM component expression may render NB cells an 
excellent target for NK cell-mediated cytotoxicity [44]. 
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Neuroblastoma Treatment 
 
A localized NB lesion is generally curable. However, long-term survival for children with 
advanced disease older than 18 months of age remains poor despite aggressive multimodal 
therapy. The therapies for these risk categories are very different. 
• Low-risk disease can frequently be cured with surgery alone. 
• Intermediate-risk disease is treated with surgery and chemotherapy. 
• High-risk NB is treated with intensive chemotherapy, surgery, radiation therapy, bone 
marrow / hematopoietic stem cell transplantation [45], biological-based therapy with 13-cis- 
retinoic acid (isotretinoin or Accutane) [46] and immunotherapy (for example anti GD2- 
monoclonal antibody usually administered with the cytokines GM-CSF and IL-2) [47]. 
With the current treatments, patients with low and intermediate risk disease have an excellent 
prognosis with cure rates above 90% for low risk and 70–90% for intermediate risk. In contrast, 
therapy for high-risk NB in the last 20 years resulted to be effective only for about 30% of 
patients. 
Chemotherapy agents used in combination have been found to be effective against NB. Agents 
commonly used for stem cell transplant conditioning are platinum compounds (cisplatin, 
carboplatin), alkylating agents (cyclophosphamide, ifosfamide, melphalan), topoisomerase II 
inhibitor (etoposide), anthracycline antibiotics (doxorubicin) and vinca alkaloids (vincristine) 
and some newer regimens include topoisomerase I inhibitors (topotecan and irinotecan) that have 
been found to be effective against recurrent disease. Many of this drugs cause a genotoxic stress 
that lead to DNA damage response (DDR) pathway activation with a consequent induction of 
ligands for NK-cell activating receptors [48] [49] [50]. 
Among the new strategies proposed to treat high-risk NB patients, the use of small molecules 
inhibitors is very promising. There are different compounds targeting proteins associated to NB. 
The most used inhibitors directly or indirectly target MYCN protein but can also affect 
downstream targets. 
BET (bromodomain and extra-terminal domain) are a family of proteins that regulate the 
transcription of many genes, including MYCN. These proteins contain 2 bromodomain motifs in 
the amino terminus and an extraterminal protein–protein interaction domain in the carboxy 
terminus, constituting an additional class of proteins that regulate chromatin structure [51] [52]. 
These “chromatin readers” bind to acetylated lysines in chromatin, recruiting additional 
chromatin, modifying proteins and leading to cell context–dependent gene activation or 
repression [53]. The BET family consists of BRD2, BRD3, BRD4, and BRDT. 
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Fig.4. JQ1 mechanism of action (Schnepp and Maris. Cancer Discov. 2013) 
 
 
JQ1 is one of the BET bromodomain inhibitor and it can represent a promising strategy to block 
the growth of MYCN-dependent NB cells [54] [55]. Indeed, it competitively binds to 
bromodomain, displacing BRD4 fusion oncoprotein from MYCN promoter (Fig. 4). 
Among MYCN downstream targets, p53 represents a good candidate because NB is rarely 
associated with p53 mutations [27]. However, the p53 pathway is often impaired in childhood 
cancers because of upstream p53/MDM2/p14ARF network aberrations [56]. One of the strategies 
to affect this pathway is by perturbing the p53/MDM2 interaction. Small molecules as Nutlin-3, 
a cis-imidazoline compound, can interact with MDM2 by mimicking the p53 N-terminal region 
where MDM2 binds and can induce p53 activation allowing its post-transcriptional acetylation 
[57]. Together with wt p53, expression level of MYCN and p14ARF may determine the outcome 
of the response to MDM2 inhibition [58]. 
The main prerequisite for p53 activation after Nutlin-3 treatment, however, is an intact p53 
protein, as p53 loss-of-function mutations inevitably prevent MDM2 inhibitors from reinstating 
p53 function [59] (Fig. 5). 
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Fig. 5. Nutlin-3a mechanism of action 
 
NK cells have an important anti-tumor activity because they can limit tumour growth. Moreover, 
especially NK cells are much less suppressed by tumor microenvironment then T cells and unlike 
B and T cells of adaptive immunity, they are capable of spontaneously destroying transformed 
cells without prior sensitization in an MHC-restricted manner [60]. The pre-clinical studies in 
mice in which NK cells are infused after allogeneic haematopoietic stem cell transplantation 
(HSCT), are very promising because suppress graft-versus-host-diseases (GVHD) and enhance 
graft-versus-tumor (GVT) against solid tumors and leukemias [61] [62]. The concurrent 
administration of NK cell stimulating cytokines, such as IL-2 or IL-15, can promote this effect 
[63]. 
Tumor-specific mAbs that recognize tumour antigens expressed on the surface of tumor cells are 
being used as cancer therapy. GD2 is a promising target for antibody therapy because it is 
abundant in most NB cells and its expression is restricted to nervous system cells among normal 
cells [64]. For this reason, an immunotherapy based on the use of anti-GD2 antibody for NB was 
investigated [47]. Anti-GD2 antibody induces ADCC via NK cells. NK cell-mediated 
surveillance mechanisms [65] and NK cell stimulation with interleukin IL-2 can also contribute 
to the antitumor effect [66]. Two intravenous (i.v.) injection of anti-GD2 IgG antibodies, 
chimeric 14.18 (ch14.18) and mouse 3F8 combined with i.v. injection of interleukin-2 (IL-2) and 
granulocyte-macrophage colony-stimulating factor (GM-CSF), have been tested in the clinic 
[47]. Despite the recent success of immunotherapy with the anti-GD2 antibody ch14.18 and 
cytokines, treatment of high-risk NB remains challenging. 
Another strategy to enhance an NK cell-mediated immunotherapy is based on genetic 
modification of cells. Such as T cells, also NK cells may be genetically engineered to display a 
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CAR enables the specific targeting or augmented cytotoxicity of NK cells. It was demonstrated 
that NK-92-scFv(ch14.18)-zeta, a GD2-specific chimeric antigen receptor expressing cell line, 
successfully lyses partially or multidrug-resistant GD2+ NB cells lines [67]. The reported side 
effects of a CAR-T cell based immunotherapy include neurologic toxicity, cytokine release 
syndrome, tumor lysis syndrome, immunogenicity [68]. For this reason, the long-lasting and 
production of pro-inflammatory cytokines from CAR-T cells in vivo is the cause of severe side 
effects [69]. NK cells have been considered better candidates for CARs because their short 
lifespans last for nearly 2 week in vivo and they mainly produce interferon IFN-γ. NK cells have 
been used for treating both hematopoietic malignancies (e.g., leukemia, lymphoma, and multiple 
myeloma) and solid tumors (e.g., melanoma, ovarian cancer, lung cancer, colorectal cancer, and 
glioblastoma) [70] [71]. NK cells have innate advantages in the treatment of certain solid tumors: 
IFN- γ has been shown to induce the permanent arrest of the growth of melanoma cells [72]; 
others solid tumors, such as the ovarian cancer, have high expression of MICA/B and ULBPs, 
which can promote NK cells function through the activating receptor NKG2D [73]. Moreover, 
recent studies have shown that IFN-γ can drive T-regulatory cells to promote antitumor 
immunity, suggesting that NK cells may contribute for the immunotherapy of solid tumors [74]. 
However, NK cell-immunotherapies for solid tumors, can control disease progression but 
scarcely abate disease [75] [76]. The possible reasons include (i) low infiltration rate of NK cells 
to the solid tumor; (ii) inhibitory factors in the tumor microenvironment; and (iii) inhibition from 
tumor cells, such as residual HLA expression. These crucial issues may be solved enhancing the 
migration of NK cells to tumor sites, altering the tumor microenvironment and combining with 
the targeting of checkpoint inhibitors aimed to activate NK cells [77].
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Fig. 6 Immunotherapy of Neuroblastoma (Nature Reviews, 2013) 
 
 
Natural Killer Cells 
 
NK cells (around 5-20% of all circulating lymphocytes) are large granular lymphocytes that 
belong to the innate immune system. Unlike T or B cells of the adaptive immune system, NK 
cells do not rearrange T cell-receptor or immunoglobulin genes from their germline configuration 
[78]. The traditional cell surface phenotype defining human NK cells within the lymphocyte gate 
on the flow cytometric analyser shows an absence of CD3 and expression of CD56, the 140-kDa 
isoform of neural cell adhesion molecule (NCAM) found on NK cells and a minority of T cells 
[79]. Murine NK cells do not express CD56 therefore NKp46, a member of the highly conserved 
natural cytotoxicity receptor (NCR) family of NK cell-activating receptors, is used to define NK 
cells across species [80] [81]. 
NK cells are part of hematopoietic system and are derived from CD34+ hematopoietic progenitor 
cells (HPCs) (Fig.7) [82], but they don’t wholly develop in the bone marrow. As a matter of fact, 
a subset of NK cells, termed CD56bright for their high-density surface expression of CD56, are 
relatively dominant in secondary lymphoid tissue (SLT) compared with their more abundant 
CD56dim NK cell counterpart found in bone marrow, blood, and spleen [83]. CD56bright NK cell 
population are less mature than the CD56dim subset, that it is characterized by an increased 
expression of NK cells [84]. In SLT, dendritic cells (DCs) and other antigen presenting cells 
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(APCs) express membrane bound IL-15, which is required for NK cell maturation, suggesting 
that SLT may be a site for NK cell development in vivo [85] 
 
 
 
Fig.7 Schematic diagram of human NK cell development. (Blood 2001) 
 
 
Conversely to T cells, NK cells can recognize viral-infected or malignant-transformed cells 
without a prior exposure and their functions are based on a balance between activator and 
inhibitor signals [86]. They are a major source of cytokines that influence the host’s immune 
response. TNF-α initiates cytokines and chemokines release that influence pro-inflammatory 
cytokine cascades, while interferon gamma (IFN-γ) production by NK cells is known to shape 
the Th1 immune response, activate APCs to further up-regulate MHC class I expression and 
improve anti-proliferative effects on viral- and malignant-transformed cells [87]. 
The majority of circulating NK CD56dim  cells share a common killing mechanism with CD8+ 
cytotoxic T lymphocytes (CTL) display against tumour target cells. NK cell killing of tumour 
cells proceeds through distinct mechanisms: (i) exocytosis of secretory lysosomes that contain 
lytic proteins such as perforin, granzymes, and (ii) NK surface expression of ligands that engage 
death receptors of the tumour necrosis factor (TNF) superfamily on tumour cells (eg, Fas, 
TRAIL) [88], thereby triggering apoptosis. In addition to antibody–independent natural 
cytotoxicity, expression of CD16 (FcγRIIIA, the low affinity receptor for IgG) on NK CD56dim 
cells mediates an antibody-dependent cellular cytotoxicity (ADCC) against IgG–coated cells 
[89]. Furthermore, NK cells can kill allogeneic cells in hematopoietic transplantation enhancing 
a graft-versus leukaemia activity [90]. Moreover, elimination of NK cells in mice results in a
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higher incidence of spontaneous tumours, impaired clearance of inoculated tumour cells, and an 
increased rate of tumour metastasis [91]. 
 
NK cell education and function 
 
NK cell education plays an important role in steady state conditions, where potentially auto- 
reactive NK cells must maintain tolerance for self, yet recognize infected or transformed cells 
after proper stimuli [92]. NK cell education is based on the signaling via the inhibitory receptors 
that recognize self-MHC class I ligand. The activation of NK cells is regulated by the integration 
of signals deriving from activating and inhibitory receptors expressed on their surface. 
 
Inhibitory receptors and their ligands. 
 
In MHC class I-sufficient humans, the NK cell’s subset lacking inhibitory receptors for self- 
MHC class I is hypo-responsive to in vitro stimulation through several activating receptors and 
fail to reject MHC class I-deficient bone marrow in vivo [93]. Thus, expression of self-MHC 
class I-reactive inhibitory receptors improve the responsive potential of NK cells [94]. Inhibitory 
NK cell receptors recognizing self-MHC class I are considered the predominant mechanism 
responsible for NK cell tolerance to self. In human, MHC class I recognition is performed by a 
distinct set of receptors called killer cell immunoglobulin-like receptors (KIRs) which are 
specific for different polymorphic MHC class I molecules. Different KIR genes have varied 
effects on NK cell activity: those KIR genes with immune-receptor tyrosine-based inhibitory 
motif in the cytoplasmic tails (indicated by L=long in the nomenclature), transmit inhibitory 
signals after binding their cognate HLA ligand; those with short cytoplasmic tails (S) including 
immune-receptor tyrosine-based activator motif transmit activating signals [95]. There are two 
main KIR haplotypes, A and B, which depend upon the genes expressed. The A haplotype 
contains up to 7 expressed genes (KIR3DL3, KIR2DL3, KIR2DL1, KIR2DL4, KIR3DL1, +/- 
KIR2DS4, KIR3DL2). KIR B haplotypes contain up to 14 genes, (KIR2DS2, KIR2DL2, 
KIR2DL5B, KIR2DS3, KIR3DS1, KIR2DL5A, KIR2DS5, KIR2DS1) and the majority of them 
is stimulatory [96]. Other inhibitory NK cell receptors for human leukocyte antigens (HLA, or 
human MHC class I) with cytoplasmic ITIMs, such as NKG2A (CD159a) and LIR-1 (ILT2, 
CD85j), also display variegated expression patterns. The ligand of NKG2A is the non-classical 
MHC class I molecule HLA-E (Fig. 8 and Fig. 9). 
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Fig.8 NK-cell receptors and their cognate ligands (CJ Chan et al. Cell Death and Differentiation 2014) 
 
 
Activator receptors and their ligands. 
 
In contrast to inhibitory receptors, most activating receptors are expressed by all NK cells. 
Furthermore, activating receptors use diverse signaling cascades, whereas inhibitory receptors 
appear to use a common mechanism for inhibition [97] [98]. Activating receptors associated with 
ITAM, can be subdivided into two groups, the first includes rapidly evolving receptors expressed 
on NK cells, such as KIR2DS, KIR3DS, and NKG2C (CD159c); some activating KIRs bind 
classical MHC class I [99], whereas NKG2C binds HLA-E [100]. Generally, the binding of 
activating receptors to MHC class I is less strong than that of their related inhibitory receptor 
counterparts (Fig. 9). 
The second group of ITAM-associated receptors, including CD16, NKp30 (CD337), and NKp46 
(CD335), are expressed on most resting NK cells. Natural cytotoxicity receptors (NCRs) NKp30, 
NKp44, and NKp46 were identified for their role in natural cytotoxicity towards tumour cells 
[101]. Recently, it was discovered that B7H6 is a functional ligand for the NK cell-activating 
receptor NKp30 [102]. Information about others NCR receptor’s ligands are not well defined. 
NK receptor for the Fc fragment of IgG (FcγR) targets immune complexes to effector cells. 
Multipe FcγRs exist, which differ in ligand affinity, cellular distribution, and effector function. 
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In human, NK cells, macrophages, and polymorphonucler cells (PMN) express FcγRIII (CD16) 
[103]. Moreover, CD16 represents the only FcγR receptor on NK cells and especially it is 
expressed on CD56dim NK cells subset [78]. Similar to both NK cell cytokine release and NK 
cell-mediated killing, CD16-mediated ADCC is tempered by inhibitory Fc receptors expressed 
on APCs, as the absence of these inhibitory Fc receptors improves the efficacy of ADCC in vivo 
[104]. In general, FcγR receptors are protein that contains two canonical Ig-like extracellular 
domains, a weakly hydrophobic transmembrane domain and a short cytoplasmic domain, (four 
amino acid) [105]. CD16 often associates with FcϵRI-γ chains or CD3-ζ chains within the cell 
membrane: both chains have an ITAM in their cytoplasmic tails [106]. Upon FcγR binding, these 
ITAMs are phosphorylated, and through the activation of PI3K, NF-κb and ERK pathways, NK 
cell degranulation, cytokine secretion, and finally tumour cell lysis occurs [107]. ADCC 
stimulates IFNγ release by NK cells activating nearby immune cells to promote antigen 
presentation and adaptive immune responses. 
CD16 is probably the best example of an NK cell receptor coupling the innate and the adaptive 
immune responses. In fact, the existence of this receptor on NK cells underlines their ability not 
only to recognize early infected and transformed target cells but also to bind the antibodies that 
are generated late during the immune response, when the adaptive immunity is activated [108]. 
 
NKG2D and DNAM-1 receptors and their ligands 
 
 
A second category of activating receptors do not contain ITAMs or associate with ITAM– 
carrying adaptors. They include NKG2D (CD314) and DNAM-1 (CD226) (Fig 9). 
NKG2D is a lectin-like type 2 transmembrane receptor expressed as a homodimer in humans by 
all NK cells [109]. It associates with the adaptor protein DAP10, which carries a 
phosphatidylinositol-3 kinase (PI3K) binding motif; the phosphorylated form of this tyrosine 
motif can bind the p85 subunit of PI3K and Grb2 [110]. In tumour microenvironment (TME), 
many cytokines regulate NKG2D expression on NK cells and its signalling. IL-15 enhances the 
surface expression of this receptor and increases also the expression of DAP10; on the other 
hands, cytokines such as IL-4 and TGFβ down regulates NKG2D and other NK cell markers 
expression in vitro and in vivo as a result to decrease NKG2D dependent cell killing [111] [112].
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Fig.9 NK-cell reactivity is determined by the balance between activating and inhibitory signals. 
(Nina Shah et al. Blood 2009) 
 
The ligands for NKG2D are self-proteins related to MHC class I molecules. In humans, these 
ligands consist of the MHC class I chain-related protein (MIC) family (e.g., MICA and MICB) 
and the UL16-binding protein (ULBP1-6) family [113]. 
Generally, NKG2D ligands are absent on the cell surface of healthy cells but are frequently 
upregulated upon cellular stress associated with viral infection and malignant transformation 
[114] and NKG2D-dependent elimination of tumour cells expressing NKG2D ligands has been 
well documented in vitro and in tumour transplant experiments [115]. In humans, NKG2D 
ligands have been described on different primary tumours. MIC and ULBP families of ligands 
are found prevalently expressed by carcinomas of the breast, lung, colon, ovary, kidney, and 
prostate, melanomas, gliomas, and leukemia. Regulation of NKG2D ligands exerts at different 
levels including transcription, mRNA stability, translation, protein stabilization, and 
excretion/shedding of ligands from cells [116] [117] [118]. DNA damage response mediated by
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ATM (ataxia telangiectasia mutated) and ATR (ATM and Rad3-related), induces the 
transcription of an array of NKG2D ligands, such as ULBP1 and ULBP2 and MIC family 
molecules [50]. In particular, ATM is recruited and activated by DNA double-strand breaks and 
is involved in several pathways, including the activation of p53 [119] which also induces 
expression of ligands for NK cell activating receptors such as ULBP1 and ULBP2 [120]. At the 
post-translational level, NKG2D ligands such MICA, MICB, and ULBPs were found to be 
cleaved from the cell surface by proteases ADAM10/17 and MMP14 and in some cases by 
tumour derived exosomes [121] [122]. 
Another NK activating receptor is DNAM-1 (CD266) that is a 65-kDa surface glycoprotein 
expressed by NK cells. DNAM-1 triggers NK cell–mediated cytolysis by promoting actin and 
granule polarization by using immunoreceptor tyrosine tail (ITT)-like motif, Grb2, and other 
downstream molecules such as Vav-1, PI3K, and phospholipase C-γ1 to activate ERK and Akt 
[123]. Moreover, in the last few years, it was underlying the recruitment and phosphorylation of 
Tyr322 and Ser329 in the DNAM-1 cytoplasmic tail for DNAM-1 adhesion and signalling [124]. 
DNAM-1 has been found to interact with the poliovirus receptor PVR (CD155) and with Nectin- 
2 (also known as CD112 or PVRL2), CD96, and TIGIT inhibitory immune receptors [125]. The 
genes for the DNAM-1 ligands, CD155 and CD112, belong to the nectins, a large family of Ig- 
like molecules involved in cell-cell adhesion [126] [127]. Additionally, the interaction of NK cell 
receptors with members of the nectin-like molecules underlines the importance of adhesion in 
the triggering of NK cell functions; it also shows that β2-integrins, LFA-1, may participate in 
triggering NK cell-mediated cytotoxicity by interacting with DNAM-1 [128] [129]. Generally, 
ligands for DNAM-1 activating receptor are not expressed on cell surface but recent studies have 
been shown that also CD155 and CD112, such as ligands for NKG2D receptor, may be up 
modulated by activating ATM/ATR pathway on tumour cells of epithelial or neuronal origin. On 
the other hand, the hypermethylation of PVR promoter-associated CpG islands induces PVR 
down-modulation in many tumours [130]. 
 
 
Nutlin 
 
Several classes of low molecular weight inhibitors of the p53-MDM2 interaction have been 
reported to be able to disrupt the binding between these proteins, then restoring p53 functions. 
Nutlins are the first selective class of cis-imidazoline small-molecules antagonist of the p53- 
MDM2 interaction. Through extensive chemical modifications of the lead compound, three 
inhibitors were ultimately obtained: Nutlin-1 and Nutlin-2 are racemic mixtures and Nutlin-3a is
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an active enantiomer isolated from racemic Nutlin-3. Nutlin-1, Nutlin-2, and Nutlin-3 disrupted 
the MDM2-p53 interaction with IC50 values of 260 nM, 140 nM, and 90 nM, respectively, with 
approximately 150- to 200-fold difference in affinity between enantiomers [57]. Among nutlins 
compounds, Nutlin-3a has been largely studied for its therapeutic potential and mechanism of 
action in human cancer. Three amino acid residues from the p53 peptide (Phe19, Trp23, and Leu26) 
are essential for the p53 binding to the MDM2 hydrophobic pocket [131]. Nutlins bind, in an 
enantiomer specific manner, to the p53 pocket on the surface of MDM2 by mimicking the 
interaction of the three critical p53 amino acid residues with the hydrophobic cavity of MDM2. 
In vitro Nutlin-3a show excellent cell permeability to cell membranes, stabilize and accumulate 
p53 in cell nuclei leading to activation of p53 pathway and the transcription of p53 target genes 
containing the p53 recognition sequence in their promoter regions (e.g., p21Waf1, MDM2). 
Although many of the p53 signal transduction components have been identified, the mechanisms 
that control the choice of p53 response and its execution are still poorly understood. Activation 
of the p53 pathway by nutlins may induces p21-dependent cell cycle arrest and/or apoptosis, but 
in normal cells, p53 activation by MDM2 inhibitors leads to cell cycle arrest and not cell death 
[132] [133] (Fig. 10). Induction of cell cycle arrest by p53 is characterized by depletion of S- 
phase cells and accumulation at G1/S (74) and/or G2/M (75) [134]. Moreover, several studies 
have shown that normal cells treated with Nutlin-3a are more resistant to apoptosis then 
transformed cells because Nutlin-3a is less toxic to normal cells than to neoplastic cells [135] 
[136]. These results suggest that p53 activation by Nutlin-3a is nontoxic to normal cells and are 
thus encouraging from a therapeutic perspective. 
 
 
 
Fig.10 Nutlin activated p53-induced pathway (Van Maerken et al. Cancer letter, 2014) 
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Another modality of action of Nutlin-3a is represented by the possibility to induce a cellular 
senescence, a characteristic irreversible cell cycle arrest. The first evidence that Nutlin-3a may 
induce cellular senescence was obtained in a model of oncogenically transformed fibroblasts 
[136]. Interestingly, a cellular senescence-like phenotype was achieved in neoplastic cells faster 
than in their corresponding primary cells, suggesting that Nutlin-3a and oncogenic signalling 
cooperate in mediating cellular senescence. A number of subsequent studies have underlined that 
senescence-like status induced by Nutlin-3a was strictly dependent on the presence of functional 
p53 [137] [138]. 
Generally, in response to genotoxic stress, p53 undergoes post-translational modifications (e.g. 
phosphorylation), but recently, various studies demonstrated that Nutlin-activated p53 is free of 
phosphorylation on six key serine residues but functions well or better as a transcription factor 
than p53 induced by two genotoxic drugs such as doxorubicin and etoposide [139]. This study 
revealed that p53 phosphorylation is not necessary for p53 activation, and that p53 transcriptional 
activity depends on its nuclear level rather than phosphorylation status. Moreover, overexpression 
of MDM2 as a result of amplification of the mdm2 gene locus has been shown to correlate well 
with wild type (wt) p53 status. 
Based on this observation, osteosarcoma cancer cell lines with the amplification of mdm2 gene 
have responded very well to nutlin treatment both in vitro and in vivo [57]. 
 
Potential therapeutic use of Nutlin-3a in tumours 
 
During the past two years, more than 160 studies have been published using Nutlin-3a to study 
potential therapeutic applications of this compound. All these studies performed in vitro and in 
animal models confirmed the anti-tumoural potential of the p53/MDM2 inhibitory approach. In 
addition, most studies demonstrated that patients with functional p53 pathway could take 
advantage of Nutlin-3a treatment. 
With respect to hematological malignancies, acute myeloid leukemia (AML), B-chronic 
lymphocytic leukemia (B-CLL), and multiple myeloma are potentially attractive tumour types for 
Nutlin-3a-based therapy, because they show a relatively low percentage of p53 deletion and/or 
mutation at diagnosis (<15%) [140]. Ex vivo experiments using AML [141], B-CLL [142], and 
multiple myeloma [143] patient specimens have indeed shown that inhibition of MDM2 by 
Nutlin-3a effectively triggers apoptosis. Moreover, Nutlin-3a synergizes with doxorubicin and 
cytosine arabinoside in killing myeloblasts in AML and with doxorubicin, chlorambucil, and 
fludarabine in killing leukemic cells in B-CLL patient specimens [144]. Importantly, the 
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combination effect of this drugs with Nutlin-3a is specific for cancer versus normal cells, as 
revealed by the lack of toxicity to peripheral blood mononuclear cells or bone marrow-derived 
hematopoietic progenitors and bone marrow stromal epithelium cells [142] [143]. In addition, it 
was demonstrated that Nutlin-3a might retain its activity in cancers missing upstream signals that 
regulate p53, such as ATM [141]. 
On the other hand, all paediatric tumours are very attractive therapeutic targets for Nutlin-3a 
treatment because most of them are p53 wt at diagnosis. A preclinical study in 
Rhabdomyosarcoma (RMS) showed that exposure to MDM2-p53 interaction inhibitor, decreased 
the viability of embryonal rhabdomyosarcoma (eRMS) and alveolar rhabdomyosarcoma (aRMS) 
cells with wt p53 compared to p53 mutated cell lines where there were only minimal changes. In 
RMS, MDM2 inhibition induced increased p53 levels and apoptosis markers (Bax, cleaved 
caspase-3 and cleaved PARP) as well as indicators of cell cycle arrest [145]. No changes were 
recorded in the mutated p53 RMS cell lines. Moreover, Miyachi et al. found Nutlin-3a induced 
increases of p53 protein through a post-transcriptional mechanism in RMS cell lines with wt p53 
as well as a dose dependent increase in the mRNA levels and protein levels of p21 and MDM2; 
by contrast, p53 mutated RMS cell lines had little effect on the mRNA and protein levels of p53, 
p21, and MDM2 [146]. 
A good cytotoxic activity of Nutlin-3a has been demonstrated also in a variety of in vitro studies 
carried out on both p53wild-type and p53null NB cell lines. Nevertheless, treatment of a subcutaneous 
neuroblastoma xenograft model with twice-daily oral Nutlin-3a (200 mg/kg) only partially 
inhibited tumour growth, despite good sensitivity (IC50 of 5.56 µM) of these cells in vitro [147] 
[148] [149]. NB cell line with wt p53 treated with Nutlin-3a show a rapid accumulation of p53 
protein, within 1–2h of treatment, and in a robust induction of p53 target gene expression, 
regardless of their differentiation status [150]. The expression levels of MYCN and p14ARF may 
determine the outcome of the response to MDM2 inhibition: knockdown and overexpression 
experiments consistently showed in these studies that both MYCN and p14ARF sensitize NB cells 
p53 wt to Nutlin-3a treatment. Gamble et al. showed that Nutlin-3a is more active in MYCN 
amplified compared with non-amplified NB cell lines, by an increased p53 transcriptional 
response, increased apoptosis and enhanced growth inhibition in MYCN amplified NB cell lines 
[58]. 
Of note, p53 is a direct transcriptional target of MYCN and its signalling pathway is potentially 
functional but impaired by MDM2 binding in MYCN amplified NB cells [27]. It was hypothesised 
that p53 antagonists such as MDM2 should be more active in MYCN amplified NB cells. Several 
studies have shown, by pre-clinical studies, the activity of the MDM2/p53 antagonist Nutlin-3a 
- 24 -  
in NB cell lines alone and in combination with conventional chemotherapy (such as cisplatin, 
etoposide and camptothecin) [151]. A synergistic antitumor effect in NB has also been 
documented when Nutlin-3a is combined with the CDK inhibitor (R)-roscovitine [152] or with 
the anti-VEGF monoclonal antibody bevacizumab [153]. An interesting observation is that 
Nutlin-3 does not only induce G1 cell cycle arrest and apoptosis in NB cells p53 wt, but also 
premature cellular senescence and neuronal differentiation depending on the cellular background 
[154]. These observations indicate that Nutlin-3 has pleiotropic activities to counteract the 
malignant phenotype of NB cells and suggest that selective MDM2/p53 inhibitors are well suited 
for treating tumours that are arrested in their differentiation, such as NB. Nutlin-3a was also able 
to induce anti-tumour activity against metastatic NB lesions, as MYCN DNA content, MYCN 
mRNA levels and the decreased amount of metastatic foci in liver and lungs Nutlin-3a treated 
mice [148]. 
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Aim of the project 
 
During my PhD I studied molecular mechanisms that induce immune-evasion response in NB and 
I explored new strategies to render NB cells more susceptible to NK cell-mediated recognition and 
lysis. The results showed here may represent the base for a new NK cell-mediated immunotherapy 
of NB. 
As reported above, the expression of ligands for NK cell-activating receptors is necessary for a 
proper anti-tumor NK cell activation and function. In particular, MICA, MICB, ULBP1, 
ULBP2/5/6 and ULBP3 ligands, are specific for NKG2D receptor and PVR and Nectin-2 ligands 
are specific for DNAM-1 receptor. In the last years, many studies showed ULBP1, ULBP2/5/6 
and ULBP3 gene expression is regulated by c-Myc and p53 transcription factors [120]. p53 and 
MDM2 are two direct target of MYCN that is the well-established marker of poor prognosis in 
NB cells and it plays a key role in several pathways involved in metastasis (angiogenesis, motility, 
and maintenance of pluripotency). 
First, based on this consideration, we asked if MYCN was involved, directly or not, in the 
expression of activating ligands. Then we tried to modulate MYCN expression by using the BET- 
bromodomain inhibitor JQ1 that, presently, is a good candidate for MYCN targeting. We explored 
also new molecular strategies to subvert MYCN function, because direct MYCN modulation is 
still very challenging. Of note, several chemotherapeutic agents have been reported to function as 
potent immune adjuvants and to be able to induce the expression of ligands for NK cell- activating 
receptors in tumour cells of different origin. Since in NB p53 gene is mutated only in 2% of the 
cases, especially in relapse, we also investigated whether the activation of DDR pathway caused 
by chemotherapeutic agents currently used in the treatment of NB, could positively affect the 
expression of ligands for NK cell-activating receptors leading to a better recognition and lysis by 
NK cells. 
Despite an initial response to intensive chemotherapy, relapse with chemoresistant disease is 
common and can rarely be solved. Moreover, the overall long-term survival of high-risk patients 
currently remains less than 50%, with survivors often having long-term toxicities as a 
consequence of the intensive chemotherapy. Thus, there is a continuing need to identify novel and 
less toxic therapies to improve survival of this group of patients. 
As reported above, Nutlin-3a is a small molecule that enhances p53 activity by disrupting the 
interaction of p53 with its inhibitor MDM2; moreover, it was studied that Nutlin-3a is less toxic 
to normal cells then to transformed cells by restoring p53 function. Of note, p53 is a direct 
transcription factor of ligands for NK cell-activating receptors [120], and promotes cellular 
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senescence, a characteristic irreversible cell cycle arrest. Interestingly, it was demonstrated that a 
cellular senescence status is necessary to induce the expression of some ligands for DNAM-1 and 
NKG2D NK cell-activating receptors [49]. Senescence-like status induced by Nutlin-3a was 
strictly dependent on the presence of functional p53. For all these reasons, by treating NB cell 
lines and primary cells with Nutlin-3a and by restoring p53 function, we aim to potentiate the 
expression of activating ligands on cancer cell surface. The effect of the small molecule Nutlin- 
3a on NB cells can be promising for a new NK cell-based immunotherapy. 
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Materials and methods 
 
Cell lines and reagents 
Human NB cell lines were obtained as follow: GICAN and ACN from Interlab Cell Line 
Collection, Banca Biologica and Cell Factory (www.iclc.it), SK-N-AS, SH-SY5Y, SH-EP, SK- 
NSH, SK-N-BE(2)c, IMR-32 from the American Type Culture Collection (ATCC), LA-N-1 from 
Creative Bioarray, LA-N-5 from the Leibniz-Institut DMSZ, SMS-KCNR from Children’s 
Oncology Group Cell Culture, while the Tet-21/N cell line was kindly provided by Dr M. Schwab 
(University of Heidelberg, Heidelberg, Germany). The human non-small-cell lung cancer cell 
line A549 was purchased from Sigma-Aldrich. All NB cell lines were characterized by (i) HLA 
class I typing by PCR-SSP sets (Genovision) according to the manufacturer’s instructions, and 
(ii) array CGH (see below). The human erythro-leukemia cell line K562 was purchased from 
ATCC and used as control target for NK cell functional assays. Cells were grown in RPMI 1640 
medium supplemented with 10% FBS (Thermo Fisher Scientific), 2 mM glutamine, 100 mg/mL 
penicillin and 50 mg/mL streptomycin (Euro Clone S.p.a.). Doxycycline (Sigma Aldrich) was 
used at 10 ng/mL. Lipofectamine 2000 was used, according to manufacturer’s instructions 
(Invitrogen), to transfect SK-N-SH cells with pIRVneoSV empty vector or pIRVneoSV-MYCN, 
both kindly provided by G. Giannini (“La Sapienza” University of Rome, Italy). Cell Tracker 
Deep Red (Thermo Fisher Scientific) was used at the final concentration of 1µM to mark 5x105 
LA-N-5 NB cell line. Cisplatin (Accord Healthcare Limited), etoposide (Teva Italia), irinotecan 
(Campo, Pfizer), and topotecan (GlaxoSmithKline) were kindly provided by the pharmacy of our 
institution. JQ1 (Selleckchem) was dissolved in DMSO and used at concentrations of 0,5 µM/L 
for LAN-5 and SH-SY5Y. 
Nutlin-3a (Cayman Chemical) was dissolved in DMSO and used at different doses at on both NB 
cell lines and NB primary cells, or at 20 and 40mg/kg (Nutlin-3a mg/mouse body weight) for in 
vivo studies. Animal experiments were conducted under the auspices of protocols approved by the 
Animal Care and Ethics Committee of the University of New South Wales (New South Wales, 
Australia). 
 
Antibodies, western blotting, flow cytometry and ROS Production. 
The following antibodies were used: anti-MYCN, anti-p53, anti-Actin (B8.4.B, FL-393 and I- 
19, respectively, Santa Cruz Biotechnology), anti-MYC (Y69, OriGene), and anti-MDM2 (2A10, 
Calbiochem-Millipore) for western blotting; antiCD107a-FITC (H4A3), anti-CD3-Alexa-700 
(UCHT), antiCD56-PE-Cy7 (B159), anti-CD45 (HI30), FITC-conjugated rat anti-mouse IgG1 
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(A85–1) and PE-conjugated rat anti-mouse IgM (R6–60.2) purchased from BD Biosciences; anti- 
ULBP1-PE  (170818),  anti-ULBP2/5/6-PE  (165903),  anti-ULBP3-PE  (166510),  anti-MICA 
(159227), anti-MICB (236511),  antiTRAIL/R2-APC  (17908), anti-CD155/PVR-PE (300907), 
antiNectin-2/CD112-APC (610603) purchased from R&D Systems; W6/32 which recognizes 
human fully-assembled MHC class I heavy chains and goat F(ab’)2 Fragment anti-mouse IgG 
FITC (IM1619, Dako) for flow cytometry; anti-MICA, antiNectin-2 (62540 and 154895, 
respectively, Abcam) and anti-PVR (Novus Biological) for immunohistochemistry assay. 
Apoptosis of tumour cells was evaluated with APC-conjugated AnnexinV (BD-Pharmingen) and 
propidium iodide (PI) (Sigma-Aldrich). ROS production was evaluated in drug-treated NB cell 
lines by using CellROX Deep Red Reagent (C10422, Invitrogen) and measured by flow 
cytometry. Flow cytometry was performed on FACSCantoII (BD Bioscences) and analyzed by 
FACSDiva Software (BD Biosciences). Whole-cell extracts were quantified by the bicinchoninic 
acid assay (Thermo Fisher Scientific), resolved on 8–10% SDS-PAGE and electroblotted. Filters 
were probed with primary antibodies followed by goat anti-mouse IgG HRP conjugated 
(Jackson). 
 
Patient samples 
Tumour samples from 12 NB patients and sections of normal intestinal mucosa and colon carcinoma, 
diagnosed at the Bambino Gesu Children’s Hospital, were used. For each patient, written informed 
parental consent and approval by the Ethical Committee of the Institution were obtained. 
 
Array CGH 
DNA from NB cell lines was tested by high-resolution array comparative genomic hybridization 
(CGH) SNP arrays. The test involved the use of a 180 K platform with a mean resolution of 
approximately 40 kb (4 x 180 platform, Agilent Technologies). A copy number variant was 
defined as a displacement of the normal value of at least three consecutive probes, and the 
mapping positions refer to the Genome Assembly hg19 (build 37). SNP-array and oligoarray data 
were analysed with Genomic Workbench 7.0.40 software (Agilent). The quality of the test was 
assessed on the strength of the QCmetrics values. Polymorphisms 
(http://projects.trag.ca/variation/) were not included because considered normal variants. 
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Senescence-associated -galactosidase (SA -Gal) activity 
Subconfluent Tet-21/N left untreated or treated with doxycycline, cultured in six-well plates, 
were fixed using 4% formaldehyde for 10 min at room temperature, washed twice with PBS and 
then stained for -gal activity at pH 6.0, according to manufacturer’s instructions (Promega). 
Images were acquired on an Olympus IX51 inverted microscope, and SA -Gal positive (blue) 
cells were counted for five fields of view (x 20 magnification) per well. 
 
ChIP analysis 
Cells were treated with formaldehyde (1% final concentration), added directly to the culture 
dishes, to cross-link protein complexes to the DNA. The reaction was stopped by adding glycine 
to a final concentration of 0.125M for 5 min at RT. Cells were washed with cold phosphate 
buffered saline, scraped and lysed in L1 buffer (2mM EDTA, 50mM Tris-HCl [pH8.1], 0.1% 
NP40, 10% Glicerol and protease and phosphatase inhibitors) for 20 min at 4°C in rotation. The 
lysates were homogenized by 15 dounce strokes and then centrifuged at 5000 rpm for 5 min at 
4°C. Nuclear pellets were resuspended in L2 buffer (5mM EDTA, 50mM Tris-HCl (pH8.0), SDS 
1% and protease and phosphatase inhibitors) and kept on ice for 10 min. Nuclear lysates were 
sonicated to obtain chromatin fragments of an average length of 200 to 500 bp and centrifuged 
at 10000 rpm for 10 min at 4°C. After determining the DNA concentrations, each chromatin 
sample was divided into aliquots of 150 µg. The sonicated supernatant fractions were diluted 10 
fold with dilution buffer (5mM EDTA, 50mM Tris-HCl (pH8.0), NP40 0.5%, NaCl 200 mM and 
protease and phosphatase inhibitors). For each condition one aliquot for the specific antibody 
(anti p53) and one aliquot for the IgG control were incubated with Protein A Sepharose, saturated 
with BSA and salmon sperm, for 3 hours at 4°C on a rotating platform. The pre-cleared chromatin 
samples were centrifuged at 14000 rpm for 5 min and incubated with the respective antibody or 
IgG overnight with gently rotation at 4°C. Immuno-precipitated samples were recovered by 
incubation with saturated protein A sepharose on a rotating platform for 3 hours at 4°C. Before 
washing, the supernatant of the IgG control was taken as input sample. After extensive washing 
(5 min at 4°C in rotation and subsequent centrifugation at 3000rpm for 2 min) with wash buffers 
(2 washes with 0.1% SDS, 1% Triton X-100, 2mM EDTA, 20mM Tris-HCl, pH 8.1, 150 mM 
NaCl; 2 washes with 0.1% SDS, 1% triton X-100, 2mM EDTA, 20mM Tris-HCl, pH 8.1, 500mM 
NaCl; 1wash with 0.25M LiCl, 1% NP40, 1% deoxycholate, 1mM EDTA, 10mM Tris-HCl, pH 
8.1; 1 wash with 10mM HCl, 1mM EDTA, pH 8.0) samples were eluted in elution buffer (100 
mM NaHCO3, SDS 1%) at room temperature while vortexing for 30 min. After the elution, 
samples were centrifuged at 13000 RPM for 5 minutes and the eluate was collected. The samples
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treated with RNAse A for 10 min at RT were incubated at 67°C over night to reverse the protein- 
DNA cross-linking. Then in each sample the NaHCO3 was neutralized with 6 µl Tris-HCl 1M 
(pH 6-7.5). After treatment with proteinase K, the DNA was extracted with phenol-chloroform, 
precipitated with ethanol and re-suspended in 50 μl of distilled water. 5 ng of the 
immunoprecipitated, IgG and input samples were used for PCR with the specific oligonucleotides 
spanning PVR promoter: PVR P 53BS 3F AGGCTGGTCTTGAACTCCTG and PVR P 53BS 
3R CCATTGCGCCACTACACTAC. The reaction was performed in triplicate using 5 ng of 
DNA, GoTaq qPCR Master Mix (Promega) and the relative qPCR primer pair in the termocycler 
“CFX Connect Real time PCR detection system” (Bio-Rad). The primer pair efficiency, the 
relative quantity of each immunoprecipitated and IgG (ΔC(t)) respect to Input sample and the 
Standard Error of the mean of the relative quantity were determined with CFX ManagerTM 
software (Bio-Rad). The percentage of the relative quantity of each immunoprecipitated sample 
was normalized respect to IgG and expressed as percentage of input chromatin (% input). 
 
Quantitative mRNA expression 
Total RNA was extracted using TRIzol Reagent (Thermo Fisher Scientific). First-strand cDNA 
was synthesized using the SuperScript II First Strand cDNA synthesis kit (Thermo Fisher 
Scientific). Quantitative real-time PCR (qPCR) reactions were performed using pre-validated 
TaqMan gene expression assays from Applied Biosystems, Thermo Fisher Scientific 
(Hs00792195_m1 for MICA, Hs00360941_m1 for ULBP1, Hs00607609_m1 for ULBP2, 
Hs00225909_m1 for ULBP3, Hs00197846_m1 for PVR, Hs01071562_m1 for Nectin-2). 
Relative gene expression was determined using the 2-ΔΔCt method and 2-ΔCt considered as 
expression level, with GAPDH (Hs02758991_g1) as endogenous control. 
 
NK cell isolation 
Human NK cells were isolated from peripheral blood mononuclear cells (PBMCs) of healthy 
donors with the RosetteSep NK-cell enrichment mixture method (StemCell Technologies) and 
Ficoll-Paque Plus (Lympholyte Cedarlane) centrifugation. NK cells were routinely checked for 
the CD3-CD56+ immunophenotype by flow cytometry and those with purity greater than 90% 
were cultured with 600 IU/mL of recombinant human IL-2 (PeproTech) at 37°C and used up to 
5 d after isolation for in vitro functional assays. NK cells isolated for in mice injections were 
expanded in NK MACS medium (Miltenyi Biotec). 
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Cytotoxicity and degranulation assay 
NK cell cytotoxic activity was tested by a standard 4-h 51Cr release assay. Degranulation assay 
was performed by co-culturing NK cells with target cells at 1:1 ratio for 3 h, in complete medium 
in presence of anti-CD107a and in the last 2 h of GolgiStop (BD Bioscence). Then, cells were 
stained with anti-CD56 and anti-CD45 and expression of CD107a was evaluated by flow 
cytometry in the CD56+CD45+ subset. Specific lysis was converted to lytic units (L.U.) calculated 
from the curve of the percentage lysis. One lytic unit is defined as the number of NK cells 
required to produce 20% lysis of 106 target cells during the 4 h of incubation. 
 
Immunohistochemistry assay 
LA-N-5 bearing NSG mice were treated intraperitoneally with DMSO or Nutlin-3a at 20mg/kg 
(drug dose/mouse body weight) and at 40mg/kg every two days for two weeks. Tumour masses 
were harvested, formaldehyde-fixed, thus paraffin-embedded blocks were cut into 3-mm sections 
and baked for 60 min at 56°C in a dehydration oven. Tissues slides from DMSO, Nutlin-3a at 
20mg/kg and at 40mg/kg masses were mounted on the same slide and parallel stained for the 
same antibody. Antigen retrieval and deparaffinization were performed on a PT-Link (Agilent 
Technologies) using the EnVision FLEX Target Retrieval Solution kits at high pH (Agilent 
Technologies) for PVR and Nectin-2, as per manufacturer’s instruction. Slides were then blocked 
for endogenous peroxidase for 10 min with a peroxidase blocking solution (Agilent 
Technologies), rinsed in the appropriate wash buffer (Agilent Technologies), and incubated for 
30 min with 5% PBS/BSA. Slides were then incubated overnight at 4°C with primary antibodies 
PVR (1:50) and Nectin-2 (1:300). Twenty minutes incubation with secondary antibody coupled 
with peroxidase (Agilent Technologies) has been subsequently performed. Bound peroxidase 
was detected with diaminobenzidine (DAB) solution and EnVision FLEX Substrate buffer 
containing peroxide (Agilent Technologies). Tissue sections were counterstained with EnVision 
FLEX Haematoxylin (Agilent Technologies). Formaldehyde-fixed paraffin-embedded blocks 
from NB patients were prepared as described above and the expression of MICA (1:200) and 
Nectin-2 (1:300) was evaluated. Sections of normal intestinal mucosa, colon carcinoma and 
kidney were used as positive controls for MICA, Nectin-2 and PVR respectively. Isotype- 
matched mouse mAbs were used as negative controls. 
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Xenograft neuroblastoma model and treatment of NSG mice 
All in vivo experiments utilized 4- to 6-week-old female NSG (NOD.Cg-Prkdcscid 
Il2rgtm1Wjl/SzJ) mice (Charles River Laboratories Italia srl), Briefly, 5 x 106 cells of LA-N-5 
NB cells resuspended in 100-mL PBS were injected subcutaneously (sc) into flank of the mice 
[155]. Mice were randomly divided into 4 groups (5 mice for each group), and treated with 1) 
control solvent, 2) Nutlin-3a, 3) IL-2 4) NK cells plus IL-2 or 5) NK cells plus IL-2 plus Nutlin-
3a. 40mg/kg of Nutlin-3a was intraperitoneally (i.p.) injected every two days for three cycles. NK 
cells were peritumorally injected 48 hours after the first Nutlin-3a injection, every 5 days, for two 
cycles. IL-2 (10x103 U/mouse) was injected i.p. every day, starting from the first NK cell 
injection and for the entire NK cell treatment. Tumour size was assessed every day by caliper 
measurement, until 45 days after LA-N-5 injection. All animal experiments were performed in 
accordance with a protocol approved by the Italian Ministry of Health and Usage Committee of 
Children's Hospital Bambino Gesù. 
 
Statistical analysis 
Digital images of western blotting were analysed by Image J (http:// 
rsbweb.nih.gov/ij/index.html) and statistical significance of densitometric values was evaluated 
by the two-tailed unpaired Student’s t-test. Normalized values were analysed for correlation by 
the regression analysis using GraphPad software. p values lower than 0.05 were considered to be 
statistically significant. 
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Results 
 
Expression of MYCN inversely correlates with that of ligands for NK cell-activating 
receptors in NB cell lines 
 
NK-cell cytotoxicity is triggered by the interaction of NK-cell activating receptors with their 
specific ligands. In particular, NKG2D receptor recognizes MICA, MICB, ULBP1, ULBP2/5/ 6 
and ULBP3 ligands [156], while DNAM1 receptor interacts with PVR and Nectin-2 ligands 
[125]. We asked whether the expression levels of the MYCN oncogene correlated with a 
mechanism of immune escape involving down-regulation of NK-cell-activating receptor ligands 
on NB cells. To investigate this possible correlation, we assessed the protein levels of MYCN by 
western blotting (Fig.12) and the surface expression of activating ligands by flow cytometry in a 
panel of 12 NB cell lines (Fig.11), including 6 MYCN non-amplified (non-MNA) and 6 MYCN 
amplified (MNA). 
Regression analysis of normalized densitometric values of western blotting and mean 
fluorescence intensity values of flow cytometry analysis revealed a significant inverse correlation 
between the expression of MYCN and that of the activating ligands MICA, MICB, ULBP1, 
ULBP2/5/6, ULBP3 and PVR. A trend toward an inverse correlation was also found between 
expression of MYCN and that of MHC class I and of Nectin-2. On the other hand, MYCN 
expression did not correlate with that of TRAIL-R2 (Fig.11). 
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Fig.11 : Scatter plots showing the correlation between MYCN and the surface expression of activating ligands for NK- 
cell receptors in twelve NB cell lines. The means of four independent immunoblot analyses of MYCN expression in NB cell 
lines are plotted against the means of fifteen independent flow cytometric analyses of surface expression of the indicated 
activating ligands; Spearman correlation r and p value are shown for each plot.* p<0.05, **p<0.01. 
 
 
c-MYC and p53 are two transcription factors involved in the induction of ULBP ligands [120]. 
Of note, p53 gene is a direct transcriptional targets of MYCN in NB [157]. 
To assess whether p53 and c-MYC could be involved in the expression of activating ligands in 
NB, the status of MYCN, c-MYC, p53 and MDM2 was evaluated in NB cell lines in terms of 
amplification, gain, deletion and protein expression by high-resolution array CGH analysis and 
western blotting (Fig.12), respectively. p53 gene was lost in four NB cell lines tested [SK-N-AS, 
ACN, SK-N-BE(2)c and LA-N-1 [158]], three of them [SK-N-AS, ACN and SK-N-BE(2)c] also 
lost MDM2 gene. c-MYC gene gain was detected in two NB cells lines (SK-N-AS and ACN), 
whereas MYCN gene amplification or gain were found in five [SK-N-BE(2)c, LA-N-1, LA-N-5, 
SMS-KCNR, IMR-32] and two (GICAN, SK-N-SH) NB cell lines, respectively (Table 2). 
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All these genetic aberrations were confirmed at the protein level, except for SK-N-BE(2)c, which 
expressed high levels of mutant p53, due to a previously reported missense mutation. 
Consistently with previously published studies, MYCN expression was inversely correlated with 
c-MYC expression. In contrast, MYCN expression directly correlated with both p53 and MDM2 
expression, as evaluated in p53 wt NB cell lines (SH-EP, GICAN, SH-SY-5Y, SK-N-SH, LA-
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N-5, SMS-KCNR, IMR-32 and Tet-21/N). This indicates that p53 is more functional in non- 
MNA NB cells, even if expressed at low levels, than in MNA NB cells in which it is inhibited 
by MDM2. 
 
 
 
 
Fig.12 MYCN is inversely correlated with c-MYC and directly correlated with p53 and MDM2 in NB cell lines Immunoblot 
analysis of MYCN, c-MYC, p53 and MDM2 in the NB cell lines indicated. An anti-Actin Ab was used for normalization. One 
representative experiment out of the five performed is shown. Scatter plots showing the correlation between MYCN and c-MYC 
(B), p53 (C) or MDM2 (D) in twelve NB cell lines. The average of densitometric values of 5 independent experiments for each 
marker is plotted; Spearman correlation r and p values value are show for each plot. 
 
 
The modulation of MYCN expression affects that of ligands for NK cell-activating- 
receptors and the susceptibility of Neuroblastoma cells to NK cell-mediated lysis 
 
To investigate whether modulation of MYCN expression could affect that of activating ligands, 
we used the conditionally MYCN-expressing Tet-21/N cell line that loses MYCN expression 
following treatment with doxycycline (Doxy). Doxycycline treatment caused a drastic down- 
regulation of MYCN expression, early induction of c-MYC expression (at 8 h) and delayed 
reduction of p53 and MDM2 expression (at 24 h) (Fig.13). Following 16 h treatment with 
doxycycline, the expression of MICA, ULBP2/5/6, ULBP3 and PVR was significantly higher in
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Doxy-treated Tet-21/N than in untreated Tet-21/N cells. Up-regulation of NK cell-activating- 
receptor ligands was detected up to 24 h after doxycycline treatment, with a peak at 16 h (Fig.14). 
 
 
 
 
Fig 13. Modulation of MYCN affects the expression of ligands for NK-cell activating receptors. Representative exemple of 
immunoblot analysis of MYCN, c-Myc, p53 and MDM2 in Tet-21/N either left untreated (0) or treated with doxycycline for the 
indicated time. An anti-actin Ab was used for normalization. Densitometry analysis of Actin-normalized proteins values of three 
independent experiments are shown. Mean ± SD; * p<0.05, **p<0.01. 
 
 
 
 
 
 
 
 
 
 
 
Fig.14    Representative 
flow cytometric analysis of 
surface  expression  of 
activating ligands for NK- 
cell receptors in Tet-21/N 
either  left untreated 
(medium, gray line) or 
treated with doxycycline 
for 16 h (Doxy, red line); 
dotted  lines,  isotype- 
matched negative controls 
(left panel). Summary of 
five independentflow 
cytometric analyses (right 
panel). p values, compared 
with untreated and Doxy- 
treated Tet-21/N cells (two- 
tailed paired Student's t- 
test); *p < 0.05, **p < 0.01.
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In Tet-21/N cell line a state of cell senescence was detected 16 h after doxycycline treatment, as 
evaluated by senescence associated-β-galactosidase (SA-β-Gal) staining (Fig.15). Three days 
after doxycycline treatment, the occurrence of cell differentiation, revealed by changes of cell 
morphology, became evident (Fig.15). This finding is consistent with results reported by other 
authors [49] on the expression of activating ligands in senescent cells, but not in mature and 
differentiated cells. 
 
 
 
Fig.15 SA-β-Gal staining and morphology of Tet-21/N cells left untreated or treated with doxycycline for 3 or 10 days, bar 
50 m. The percentage of SA-β-Gal positive cells, evaluated from 5 different fields for each condition, by counting at least 200 
cells per field, is reported, mean ± sd (right panel), (two-tailed paired Student t test) *p<0.05, ***p<0.001. 
 
 
To further confirm that MYCN expression affects that of ligands for NK cell-activating- 
receptors, we transiently transfected a non-MNA NB cell line as SK-N-SH with piRV-neoSV 
vector bearing MYCN cDNA (SK-N-SH-MYCN) or the empty vector (SK-N-SH-ctrl) as control. 
The overexpression of MYCN, peaking at 16 h and gradually decreasing until 72 h, induced 
downregulation of c-MYC (from 16 to 72 h) and upregulation of both p53 (from 16 to 48 h) and 
MDM2 (from 16 to 24 h), as revealed by western blotting (Fig.16). SK-N-SH-MYCN cells 
showed decreased surface expression of activating ligands as compared with SK-N-SH-ctrl cells, 
significantly evident 48 h after transfection. 
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Fig.16 Representative example of immunoblot analysis of SK-N-SH either left transfected with empty vector (ctrl) or with 
piRVneoSV-MYCN (MYCN) for the indicated time (left panel). Densitometry analysis of Actin-normalized proteins values of 
three independent experiments are shown (right panel). 
 
 
SK-N-SH-MYCN cells showed decreased surface expression of activating ligands as compared 
with SK-N-SH-ctrl cells, significantly evident 48 h after transfection (Fig.17). 
 
Fig.17. Representative 
flow cytometric analysis of 
surface expression of 
activating ligands for NK- 
cell receptors in SK-N-SH 
transfected for 48 h with 
control vector (ctrl, gray 
line) or with MYCN cDNA 
vector (MYCN, blue line); 
dotted lines, isotype-
matched negative controls 
(left panel). 
Summary of five 
independent flow 
cytometric analyses (right 
panel). p values, compared 
with ctrl and MYCN 
cDNA vector transfected 
cells (two-tailed paired 
Student's t-test); *p < 
0.05,**p < 0.01.
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Later, to test whether the increased expression of NK cell-activating receptor ligands induced by 
MYCN modulation could affect NK cell-mediated recognition of NB cells, we performed 
degranulation and cytotoxicity assays using untreated and Doxy-treated Tet-21/N cells, as well 
as SK-N-SH-ctrl and SK-N-SH-MYCN cell lines as targets. After 16 h treatment with 
doxycycline, Tet-21/N cells were significantly more susceptible to NK cell-mediated lysis than 
untreated cells in both degranulation and cytotoxicity assays. Conversely, SK-N-SH-MYCN cell 
lines were less susceptible to NK cell recognition and lysis, compared with control cells, as 
evaluated in both degranulation and cytotoxicity assays (Fig. 18). 
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Fig. 18. Modulation of MYCN renders NB cells differently susceptible to NK-cell-mediated lysis. (A) Degranulation of 
human CD3−CD56+ CD45+ NK cells from healthy donors, measured as CD107a cell-surface expression following stimulation 
with Tet-21/N cells, either left untreated (medium) or treated with doxycycline for 16 h (Doxy). K562 cells were used as positive 
control. The percentage of CD107a+ NK cells is indicated. A representative experiment out of the eight performed is shown (left 
panel). Summary of NK-cell degranulation of cells isolated from eight healthy donors is shown (right panel). Dots, percentage 
of CD107a+ NK cells; horizontal bars, average values. Dashed lines connect percentage of CD107a+ NK cells from each donor 
cells. p values, compared with untreated and doxycycline-treated Tet-21/N cells (two-tailed paired Student's t-test). (B) Tet-21/N 
untreated or treated as in (A) were tested as targets for NK cells at the indicated effector:target (E:T) ratios in a standard 51Cr- 
release assay. One representative experiment out of the five performed is shown (left panel). p values, compared with untreated 
and doxycycline-treated Tet-21/N cells (two-tailed paired Student's t-test); *p < 0.05, **p < 0.01. Summary of cytotoxic assay of 
Tet-21/N cells treated as in A and tested as targets of NK cells isolated from five healthy donors in a standard 51Cr-release assay 
(right panel). Specific lysis was converted to L.U. 20%. Dots, L.U. 20% of the effector/target pairs tested; horizontal bars, average 
values. Dashed lines connect L.U. 20% from each donor cells obtained with the indicated target. p values, compared with 
untreated and doxycycline-treated Tet-21/N cells (two-tailed paired Student's t-test). (C) Degranulation assay of human NK cells, 
as in (A), following stimulation with SK-N-SH cells transfected for 48 h with piRVneoSV vector (ctrl) or with piRVneoSV- MYCN 
(MYCN). One representative experiment out of the six performed (left panel) and the summary of six experiments (right panel) 
are shown. (D) Cytotoxic activity of healthy donor NK cells, as in (B), against SK-N-SH cells transfected for 48 h with ctrl or 
MYCN cDNA vector. One representative experiment out of the five performed (left panel) and the summary of five experiments 
(right panel) are shown. 
 
The expression of MYCN in primary Neuroblastoma samples is inversely correlated with 
that of ligands for NK cell-activating receptors 
 
Next, the expression of MYCN and that of MICA, ULBP1, ULBP2, ULBP3, PVR and Nectin-2 
was investigated in 12 different primary neuroblastoma samples by qPCR. Similarly to NB cell 
lines, MYCN expression was inversely correlated with that of activating ligands also in NB 
patient samples (Fig.19). A significant inverse correlation between the expression of MYCN and 
that of MICA and Nectin-2 was detected. 
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Fig.19. Expression of MYCN and of NK-cell-activating 
receptor ligands in primary NB cells. qPCR analysis of 
MYCN and the indicated activating ligands in 12 primary 
NB samples. GAPDH was used for normalization. Data were 
normalized as percentages of the highest value obtained for 
each marker and plotted as percentage of expression levels. 
Data are representative of four experiments. Scatter plots 
showing the correlation between MYCN and both MICA and 
Nectin-2 in 12 NB samples. The means of four independent 
qPCR analyses, expressed as percentage of expression 
levels, of MYCN are plotted against those of MICA and 
Nectin-2; Spearman correlation r and p value are shown for 
each plot 
 
 
 
 
 
 
Thus, high levels of MYCN expression corresponded to low levels of expression of activating 
ligands and vice-versa, with the exception for some activating ligands in patients 6, 12 and 8. 
Interestingly, primary sample from patient 12 expressed moderate levels of MYCN and high 
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levels of ULBP1 and ULBP2. Notably, this patient had 4S NB, a tumour characterized by high 
rate of spontaneous regression [159]. 
Finally, the expression of MICA and that of Nectin-2 protein was evaluated by 
immunohistochemical assay in primary NB samples from patient 11 and 3 that displayed 
markedly different expression of MYCN mRNA and of activating ligands (Fig.20). The stroma-
poor tumour from patient 11, characterized by MYCN gain and low differentiation grade, showed 
low expression of both MICA and Nectin-2 (Fig 20 upper panels). By contrast, the stroma-rich 
tumour from patient 3, characterized by undetectable MYCN expression (lower panels), with 
mature differentiation grade, showed high expression levels of both MICA and Nectin-2 in 
ganglion cells. Thus, the inverse correlation between the expression of MYCN and MICA and 
Nectin-2 ligands, detected at the mRNA level, was confirmed at the protein level in primary NB 
samples. 
These data has been published in the journal OncoImmunology [160]. 
 
 
 
 
Fig.20. Expression of MICA and Nectin-2 in primary NB samples by immunohistochemistry assay. MICA and Nectin-2 
expressing cells are shown in brown. Nuclei are counterstained with hematoxylin (blue). Original magnification, ×20. Scale bars 
30 µm. 
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JQ1 negatively affects the activating ligands expression for NK cell-activating-receptors 
in NB 
 
In view of these data, we explored molecular strategies aimed to inhibit MYCN functions. We 
used JQ1 (BET bromodomain inhibitors) to investigate its effect on the expression of activating 
ligands. 
The MYCN non-amplified (non-MNA) SH-SY5Y and both MYCN-amplified (MNA) LA-N-5 and 
IMR-32 NB cell lines were cultured in the presence of JQ1 at different doses for 24, 48 and 72 
hours in order to identify optimal conditions enabling cell viability and preventing apoptosis 
which could compromise the surface expression of ligands. Cell viability and apoptosis were 
assessed by cell count and AnnexinV/PI staining, respectively. The dose of 0,5 M did not affect 
cell growth (Fig. 21A) or apoptotic state (Fig. 21B) compared with higher drug doses at all three 
time points tested. At 72 hours IMR-32 cell line was more sensible to JQ1 treatment compared 
with the others NB cell lines, as evaluated by important cell arrest and apoptosis induction even 
at low JQ1 doses. 
 
Fig.21 Cell count and apoptotic state of NB cell lines upon JQ1 treatment. NB cell lies SH-SY5Y,  LAN-5 and IMR-32  were 
untreated (DMSO) or treated with JQ1 at the indicated concentrations for 24, 48 and 72h. (A) Cell count of NB cell lines at each 
condition was measured by trypan blue exlusion-based method. (B) Apoptosis state was evaluated by AnnexinV/PI staining and 
flow cytometry analysis. The percentage of cells in the early phase of Apoptosis (AnnexinV+PI-, blu bar), in the late phase of 
apoptosis (AnnexinV+PI+, orange bar) and dead cells (AnnexinV-PI+, gray bar) are indicated in stacked histogram. A 
representative experiment out of three performed is shown. 
Then, we performed western blotting analysis to evaluate the effect of JQ1 on the expression 
level of MYCN, together with that of c-MYC, p53 and the two main p53 functional readouts, 
MDM2 and p21. As shown in Fig. 22A, JQ1 treatment (0,5 M for 24h, 48 or 72 hours for both 
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SH- SY5Y and LA-N-5, and for 24 or 48 hours for IMR-32) efficiently downregulated MYCN 
in NB cell lines, with more evident effects on the MNA LA-N-5 cell line and on IMR-32 already 
at 24h. JQ1 downregulated also c-MYC as evident in SH-SY5Y, consistent with the fact that the 
promoter of c-MYC shares BET-bromodomains with that of MYCN oncogene [161]. These data 
indicate that in NB cell lines JQ1 impaired the expression of c-MYC, one of the two transcription 
factors known to regulate the expression of ligands for NK cell-activating receptors [162]. 
Moreover, p53 protein levels were very weakly increased upon JQ1 treatment with a significant 
decrease of MDM2 and no effect on p21 (Fig. 22A). We supposed that the weak increase of p53 
levels results from the balance of a double mechanism i) the p53 molecular stabilization mediated 
by the reduced levels of MDM2 and ii) the p53 down-regulation mediated by the reduced levels 
of MYCN. Thus, consequently, the weak increase of p53 operated by pre-apoptotic dose of JQ1 is 
not functional enough as evaluated by the unmodified p21 level. These data suggest that the only 
down-regulation of MYCN mediated by JQ1 is not sufficient to restore p53 function.  
 
 
 
Fig.22 Expression levels of c-MYC, p53 and ROS production in JQ1-treated NB cell lines 
NB cell lines SH-SY5Y, LA-N-5 and IMR-32 were either treated with DMSO as control or 
with a pre-apoptotic dose of JQ1 (0.5 M) for the time indicated. (A) Representative example 
out of three independent experiments of immunoblot analysis of MYCN, c-MYC, p53, MDM2 
and p21 (left panel of each cell line). An anti-actin Ab was used for normalization. 
Densitometry analysis of actin-normalized protein values are shown (right panel of each cell 
line). (B) NB cell lines were treated with DMSO or 0.5 M of JQ1 for 48 hours and ROS 
production was measured by flow cytometry. ROS levels were expressed as mean ± SD of MFI 
obtained by four independent stainings for each NB cell lines and were reported in histograms 
(two-tailed unpaired Student’s t-test); **p<0.01, ***p<0.001, ****p<0.0001. 
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Moreover, we evaluated the levels of ROS, extensively reported to be correlated with the 
expression of ligands for NK cell-receptors [164, 178, 179], in JQ1-treated NB cell lines. As 
shown in Fig 2B, 0.5 M of JQ1 at 48 hours strongly down-regulated the levels of ROS in all 
three NB cell lines (Fig.22B). These data were in line with other evidences in tumours showing 
the down-regulation of ROS levels operated by JQ1 treatment, by affecting several BRD4 genes 
involved in ROS production [180, 181]. Overall, these data indicate that pre-apoptotic dose of 
JQ1 in NB cell lines, not only impaired c-MYC expression and do not restore the impaired p53 
function, but also affect a stress-induced event as ROS production, all these crucial factors 
involved in the induction of activating ligands. The effect of JQ1-mediated MYCN 
downregulation was evaluated on surface expression of activating ligands by flow cytometry 
analysis. The expression levels of ULBP1, ULBP3, PVR and Nectin-2 were significantly 
downregulated in both SH-SY5Y, LA-N-5 and IMR-32 cell lines upon JQ1 treatment (Fig. 23). 
These data indicate that in spite of an efficient MYCN downregulation mediated by JQ1, the 
impaired function of both c-MYC and p53 led to a compromised expression of their target genes 
for activating ligands. 
 
 
Fig.23 JQ1 downregulates the expression of ligands for NK cell-activating receptors  
NB cell lines SH-SY5Y, LA-N-5 and IMR-32 were treated with DMSO (blue bar) or JQ1 (0.5 M, red bar) for 48 hours and 
surface expression of ligands for NK cell-activating receptors was evaluated by flow cytometry analysis. Representative flow 
cytometry analysis of surface expression of each ligands for NK cell-activating receptors (right panel) and the summary of five 
independent experiments (left panel) were reported. p values, compared DMSO- and JQ1-treated NB cell lines (two-tailed 
unpared Student’s t-test); *p<0.05, **p<0.01, ***p<0.001. 
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These results were consistent with our previous data regarding the modulation of MYCN through 
a Tet-off cellular model in which we appreciated the increase of activating ligands only in 
conditions of up-modulation of c-MYC and p53 [160]. Here, these evidences confirmed that the 
MYCN downregulation molecular strategies aimed to cure NB should be accomplished by a 
sustained activation of p53 and all the events, excluding those inducing side effects (such as c-
MYC up-modulation), involved in the induction of ligands for NK cell-activating receptors.  
 
JQ1-treated NB cell lines are less susceptible to NK cell-mediated recognition and killing 
 
 
To evaluate if the decreased expression levels of activating ligands could affect NK cell-mediated 
recognition and killing of NB cells, we performed both NK cell degranulation and 51chromium 
release assay using DMSO- and JQ1-treated NB cell lines as targets. Consistently with the 
decreased levels of activating ligands, JQ1-treated NB cell lines were significantly more resistant 
to NK cell-mediated degranulation and cytotoxicity (Fig. 24A-B). 
 
 
 
Fig. 24 JQ1 renders NB cell lines more resistant to NK cell-mediated recognition and lysis.  
DMSO and JQ1-treated SH-SY5Y, LA-N-5 and IMR-32 cell lines were used as target cells in NK-cell functional assays. (A) 
Degranulation of human CD3-CD56+CD45+ NK cells isolated from healthy donors, measured as cell surface expression of 
CD107a marker, following stimulation with SH-SY5Y, LA-N-5 and IMR-32, either treated with DMSO or JQ1 (0.5 M) for 48 
hours. K562 cell line was used as positive control. The percentage of CD107a+ NK cells is indicated. A representative experiment 
out of ten performed is shown (left panel). Summary of NK cell-degranulation of cells isolated from ten healthy donors is shown 
(right panel). Dots, percentage of CD107a+ NK cells; horizontal bars, average values. (B) DMSO and JQ1-treated SH-SY5Y, 
LA-N-5 and IMR-32 cell lines were used as targets cytotoxic assay of NK cells isolated from five healthy donors by standard 
51Cr-release assay at the indicated effector:target (E:T) ratios in a standard 51Cr-release assay. One representative experiment out 
of the five performed is shown (right panel). Specific lysis was converted to L.U. 20%. Summary of cytotoxic assays of NK cells 
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isolated from five healthy donors are reported (left panel). Dots, L.U. 20% of the effector/target pairs tested; horizontal bars, 
average values. In A and B, p value, compared with DMSO- and JQ1-treated NB cell lines (two-tailed unpaired Student’s t-test); 
*p<0.05, **p<0.01, p<0.001***. 
 
These data suggested that JQ1, the most efficient drug inhibiting MYCN oncogene functions, 
does not show immunomodulatory capacity in terms of induction of ligands for NK cell- 
activating receptors and NK cell anti-tumour activity in NB cell lines. 
All these data regarding JQ1 treatment of NB cells have been submitted to an indexed journal and 
presently are under review. 
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Drugs Used for NB Treatment Did Not Induce the Expression of Ligands for NKG2D- and 
DNAM1-Activating Receptors on NB Cell Lines 
 
It was demonstrated that p53 is a transcriptional factor for ULBP1 and ULBP3 and since it is 
mutated only in 2% of NB cases [13], we investigated whether drugs commonly used in the 
treatment of NB could induce the activation of DDR pathway that, of note, is involved in p53 
function. The genotoxic drugs cisplatin (DNA binder), etoposide (topoisomerase II inhibitor), 
irinotecan, and topotecan (topoisomerase I inhibitors) were used to treat in vitro the following 
NB cell lines: SK-N-AS, SH-SY5Y, SH-EP, SK-N-SH, SK-N-BE(2)c, LA-N-5, and IMR-32. 
These cell lines were cultured with cisplatin at 2 μM, etoposide at 0,1 μM, irinotecan at 1M and 
topotecan at 10 nM for 24h without inducing apoptosis. For this reason, 24h drug treatment was 
the best time point to evaluate the levels of activating ligands. Under these conditions, cisplatin, 
etoposide, irinotecan, and topotecan did not induce the expression of MHC class I molecule 
ligands for activating killer-immunoglobulin-like receptors (KIRs), MICA, MICB, ULBP1, 
ULBP2/5/6, ULBP3 ligands for NKG2D, PVR, and Nectin2 ligands for DNAM1 and TRAIL-
R2 interacting with TRAIL. Some exceptions were found for the induction of ULBP2/5/6 on SK-
N-AS and IMR-32 by etoposide and of Nectin2 on SK-N-AS and SH-EP by topotecan and 
irinotecan, respectively (Fig. 25). 
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Fig.25. Anticancer drugs do not affect the expression of ligands for NK cell-activating receptors in NB cell lines. The NB 
cell lines SK-N-AS, SH-SY5Y, SH-EP, SK-N-SH, SK-N-BE(2)c, LA-N-5, and IMR-32 were untreated (un) or treated with 
cisplatin (at 2 μM), etoposide (at 0,1 μM), irinotecan (at 1  nM), and topotecan (at 10  nM) for 24 hours, and the surface expression of 
each indicated ligands for NK cell-activating receptors was analysed by flow cytometry. The surface expression of activating 
ligands was expressed as mean fluorescence intensity (MFI) that was normalized to MFI of IgG isotype Ab used as control (MFI 
fold change). The mean ± SD of MFI fold changes obtained by 5 independent stainings of each drug-treated NB cell line are 
reported in histograms (two-tailed paired Student's t-test) (∗∗ p < 0.01). 
 
These data suggest that the drugs commonly used for chemotherapy of NB patients, induce apoptosis 
of p53 wild-type NB cell lines and, at pre-apoptotic concentrations, do not induce the expression of 
activating ligands. Thus, these drugs do not exert immune adjuvant effects on antitumor NK cell-
mediated functions.  
 
ATM, ATR, CHEK1, and CHEK2 Status on NB Cell Lines 
 
 
To assess if the impaired modulation of activating ligands by the four drugs tested could be 
related to altered signalling upon drug-mediated genotoxic DNA damage, the status of genes 
encoding ATM (ATM), ATR (ATR), Chk1 (CHEK1), and Chk2 (CHEK2), the main molecules 
involved in DDR, was analysed in our panel of NB cell lines (Table 3). a-CGH revealed that the 
ATM gene was normal in SH-SY5Y, SK-N-SH, and LA-N-5 but was lost in SK-N-AS, SH- EP, 
and IMR-32. By contrast, the status of the ATR gene was normal in all NB cell lines with the 
exception of SK-N-AS and SH-EP in which ATR gain was detected. In addition, the status of 
genes for checkpoint kinases was shown to be partially altered: CHEK1was lost in both SK-N- 
AS and IMR-32, CHEK2 was lost in both SK-N-AS and SK-N-BE(2)c, and both were normal in 
all other cell lines. Moreover, ATM and CHEK1 were subjected to copy-neutral loss of 
heterozygosity (cnLOH) in SK-N-BE(2)c. cnLOH represents one example of genomic 
abnormality in which no change in chromosomal copy number occurs and is often associated 
with resistance to standard therapeutic modalities and poor survival in tumours [163]. 
Interestingly, SK-N-BE(2)c showed a large region of cnLOH (79.7 Mb) that included ATM and 
CHEK1 genes. Thus, cnLOH can lead to an effective knockout of gene expression. 
These data suggest that the impaired induction of the expression of activating ligands upon DDR 
was due at least in part to the loss of ATM, CHEK1, and CHEK2 and the gain of ATR in NB cell 
lines tested. Additional molecules involved in the DDR pathway triggered by genotoxic drugs 
and leading to defective modulation of activating ligand expression in NB cells should be 
investigated. 
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Tab.3 ATM, ATR, CHEK1, and CHEK2 Status on NB Cell Lines 
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ROS Production and p53 Stabilization in NB Cell Lines upon Cisplatin, Etoposide, 
Irinotecan, and Topotecan Treatment 
 
The production of ROS in genotoxic drug-treated tumour cells has been associated with the 
induction of NKG2D and DNAM1 ligands [164]. Then, wt p53 NB cell lines SH-SY5Y, SH-EP, 
SK-N-SH, LA-N-5, and IMR-32 were treated for 24h with cisplatin, etoposide, irinotecan, and 
topotecan at the above-mentioned concentrations, and ROS levels were measured by flow 
cytometry. Both LA-N-5 and IMR-32 produced ROS upon incubation with the four drugs, with 
the exception of LA-N-5 after etoposide treatment. SK-N-SH produced ROS after cisplatin and 
etoposide but not irinotecan and topotecan treatment. SH-SY5Y produced ROS only after 
topotecan treatment, whilst SH-EP was completely refractory to generate ROS upon the 
treatment of all drugs used. Then, to assess if our genotoxic drugs at the doses reported above 
induced the stabilization of p53 in NB cell lines, the wt p53 ATM single copy LA-N-5 NB cell 
line was treated with cisplatin, etoposide, irinotecan, or topotecan for 2, 5, and 8h, and the level 
of p53 was evaluated by Western blotting. LA-N-5 cells showed higher levels of p53 2 hours 
after drug treatment, particularly evident after cisplatin and etoposide treatment that returned to 
normal levels at latter time points. 
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Fig.26 ROS production and p53 stabilization in drug-treated NB cell lines. (A) NB cell lines were untreated (UN) or treated 
for 24 hours with cisplatin, etoposide, irinotecan, and topotecan, at the same concentrations described in Fig.14, and ROS 
production was measured by flow cytometry. Drug-induced ROS levels were expressed as MFI normalized to MFI of untreated 
cells used as control (MFI fold change). The mean ± SD of MFI fold changes obtained by 4 independent stainings of each drug- 
treated NB cell line are reported in histograms (two-tailed paired Student’s t-test) (∗p < 0 05, ∗∗p < 0 01). (B) LA-N-5 was 
untreated (0) or treated with the same drugs at the same doses described above for 2, 5, and 8 hours, and levels of p53 were 
measured by immunoblot analysis. An anti-actin Ab was used for normalization. Densitometric analysis of p53 normalized to 
actin and relative to untreated cells (point 0) are reported below each immunoblot. A representative out of two independent 
experiments performed is shown. 
 
 
These data indicate that the impaired induction of ligands for NK cell-activating receptors in NB 
cell lines upon pre-apoptotic doses of genotoxic drugs could depend also on the abnormal 
production of ROS and on the transient rather than persistent p53 stabilization. 
 
 
Cisplatin Does Not Render NB Cell Lines More Susceptible to NK Cell-Mediated 
Recognition 
 
 
To test whether the impaired, genotoxic drug-dependent modulation of ligands for NK cell- 
activating receptors in NB cell lines affected NK-cell-mediated recognition, we performed an 
NK cell degranulation assay by using drug-treated NB cell lines as target cells. Cisplatin was 
previously reported to induce the MICA and MICB expression in non-small-cell lung cancer 
A549 cell line, through DNA stress-induced ATM-ATR signalling, resulting in enhanced 
sensitivity to NK cell-mediated cytotoxicity [165]. Therefore, we tested the A549 cell line as a 
positive control to compare the susceptibility of cisplatin-treated SH-SY5Y and LA-N-5 NB cell 
lines to NK cell-mediated recognition. We performed an NK cell degranulation assay by using 
as target the A549 cell line treated with 10 μM of cisplatin for 48 hours and both SH-SY5Y and 
LA-N-5 cell lines treated with 2 μM of cisplatin for 24 hours. The cisplatin treated A549 cell line 
was significantly more susceptible to NK cell recognition than untreated cells, as previously 
reported. In contrast, cisplatin-treated SH-SY5Y and LA-N-5 NB cell lines induced NK cell 
degranulation comparably to untreated cells (Fig. 27). These data confirm that genotoxic drugs 
such as cisplatin do not render NB cell lines more susceptible to NK cell recognition. 
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Fig.27 Cisplatin does not sensitize NB cell lines to NK cell recognition. The NB cell lines SH-SY5Y and LA-N-5 were 
untreated (medium) or treated with 2 μM of cisplatin for 24 hours and used as targets in an NK cell degranulation assay, measured as 
the CD107a cell-surface expression on human CD3−CD56+CD45+ NK cells from healthy donors. The K562 cell line was used 
as positive control for NK cell activation. The A549 cell line was untreated or treated with 10 μM of cisplatin for 48 hours and 
used as positive control for drug effect. (a) A representative experiment out of five performed is shown. The percentage of 
CD107a+ NK cells is indicated. (b) Summaries of NK cell degranulation of NK cells, isolated by five different healthy donors, 
following stimulation with untreated and cisplatin-treated cell lines are shown. Dots, percentage of CD107a+ NK cells; horizontal 
bars, average values. p value compared untreated with cisplatin-treated cell lines (two-tailed paired Student's t-test) (∗∗∗ p < 
0.001). 
 
 
In conclusion, based on these data and concepts, in order to boost the NK cell-mediated 
immunotherapy of NB, the combined use of immune adjuvant agents could represent a winning 
approach. Thus, the effect of molecules efficiently inducing the expression of ligands for NK 
cell-activating receptors on NB cells remains to be evaluated. 
All these data regarding the drug effects on NB cells have been published in the Journal of 
Immunology Research [166]. 
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Nutlin-3a enhances the expression of ligands for NK cell-activating receptors and renders 
NB cell lines more susceptible to NK cell-mediated recognition and lysis. 
 
Since we evaluated both NB refractoriness to genotoxic drugs and the inefficient JQ1-mediated 
targeting of MYCN in inducing the expression of ligands for NK cell-activating receptors in NB 
cells, we needed to explore other molecular strategies. Considering that the expression of such 
ligands depends on the function of the crucial transcription factor p53 [120], we evaluated the 
effect of the small molecule Nutlin-3a on NB cells that is known to be able to promote p53 
function despite the upstream signals that regulate p53 are altered. 
For this reasons, both non-MNA (SH-SY5Y p53 wt and SK-N-AS p53 mut), and MNA (SMS- 
KCNR, LA-N-5, both p53 wt and SK-N-BE2C p53 mut) cell lines undergone to Nutlin-3a 
treatment. A dose-response curve, at 24h and 48h, was performed to set the right dose to not 
induce an apoptotic effect. Analysis of normalized densitometric values of western blotting, 
analysed at 48h with progressive increase in the Nutlin-3a concentration (0,5-1-2-3-10 M), 
show a significant increase in MDM2, p53 and p21 levels in SH-SY-5Y, SMS-KCNR and LA- 
N-5 but not in SK-N-AS and SK-N-BE2C cell lines. MYCN shows no expression changes in all 
cell lines (Fig.28). Mean fluorescence intensity values of flow cytometry analysis performed at 
48h with a drug concentration of 2M, revealed a strong and significant up-modulation of 
ULBP1, ULBP2/5/6, ULBP3 and PVR activating ligands in SMS-KCNR and LA-N-5 cell lines, 
both MNA and p53 wt. A less but still significant increase in ULBP1 and ULBP3 activating 
ligands is evident in non-MNA p53 wt SH-SY-5Y cell line. No result in terms of activating 
ligands up-regulation can be detected in SK-N-AS (non-MNA) and SKNBE2C (MNA) cell lines, 
both p53 mut (Fig.28). 
Therefore, we can say Nutlin-3a is a drug able to induce the activating ligand expression on 
MYCN amplified NB cell lines. 
  
Fig.28 Immunoblot analysis in NB-cells either 
untreated (DMSO) or treated with Nutlin-3a at the 
indicated concentrations for 24 hours (left panel 
of each cell line). Flow cytometry analysis of 
surface expression of activating ligands in NB cell 
lines left untreated (DMSO, grey bar) or treated 
with Nutlin-3a at 2M (red bar) for 48 hours. 
Summary of five independent flow cytometry 
analyses (panel below each cell line). p values, 
compared DMSO and Nutlin-3a-treated NB cell 
lines (two-tailed pared Student’s t-test); 
*p<0.05, **p<0.01. 
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To test if the induced expression of ligands for NK cell-activating receptor mediated by Nutlin- 
3a may affect NK cell-mediated recognition and lysis, we performed degranulation and cytotoxic 
assays after 48h in LA-N-5 and SMS-KCNR cell lines. We observed that cells treated with 
Nutlin-3a were significantly more susceptible to NK cell-mediated lysis than those with DMSO 
as control. 
LAN5 LAN5 
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Fig. 29 Degranulation of human CD3-CD56+CD45+ NK cells from healthy donors, measured as CD107a cell-surface expression 
following stimulation with LA-N-5 and SMS-KCNR, either left untreated (DMSO) or treated with Nutlin-3a at 2M for 48 hours. 
K562 cells were used as positive control. The percentage of CD107a+ NK cells is indicated. A representative experiment out of 
the ten performed is shown. Summary of NK cell-degranulation of cells isolated from ten healthy donors is shown. Dots, 
percentage of CD107a+ NK cells; horizontal bars, average values. DMSO or Nutlin-3a-treated NB cell lines as in A were used 
as targets for NK cells in a standard 51Cr-release assay. Summary of cytotoxic assay of NK cells isolated from healthy donors, 
six for LA-N-5 and five for SMS-KCNR. Specific lysis was converted to L.U. 20%. Dots, L.U. 20% of the effector/target pairs 
tested; horizontal bars, average values. p value, compared with DMSO and Nutlin-3a-treated NB cell lines (two-tailed paired 
Student’s t-test). *p<0.05, **p<0.01, ***p<0.001. 
 
PVR is upregulated at the transcriptional level and it is direct p53 target gene. 
 
 
Next, we analysed whether ligands for NK cell-activating receptors were upregulated at the 
transcriptional level by quantitative real-time PCR. Surprisingly, PVR mRNA (relative by 3- 
fold) was strongly upregulated upon induction of p53 after 16 h Nutlin-3a treatment in LA-N-5 
p53 wt cell line (Fig. 30A). 
In a next step, we investigated whether the transcriptional upregulation of PVR involved a direct 
p53 binding to PVR promoter. Bionformatic analisys by Trap and Genomatix Mathinspector 
software revealed three putative p53-binding sites on PVR promoter region. In addition, we 
performed the chromatin immunoprecipitation (ChIP) with a p53-specific mAb in LA-N-5 cells 
untreated or treated with Nutlin-3a for 16 hours that revealed a binding of p53 wt to a specific 
region on PVR promoter in LA-N-5 cells upon Nutlin-3a treatment (Fig. 30B). The binding of 
p53 to PVR promoter was quantified by qPCR indicating an increase of 2,7 fold compared with 
untreated cells. Of note, in the same experimental conditions, no binding using the p53-specific 
mAb on a glyceraldehyde-3-phosphate dehydrogenase (GAPDH) sequence was detected by ChIP 
ruling out nonspecific precipitation. Altogether, these data show that PVR mRNAs is upregulated 
by a direct binding of p53 to PVR promoter in LA-N-5 cell line after Nutlin-3a treatment.
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Fig. 30 p53-binding site in PVR gene. A qPCR analysis of PVR in LA-N-5 NB cell line. One representative experiment of 5 
indipendent qPCR is shown. GAPDH was used for normalization B Binding of p53 to p53-binding site in the PVR gene promoter 
was analysed in LA-N-5, either untreated (DMSO) or treated with Nutlin-3a (2µM) for 16 hours, by ChIP assay. The amount of 
immunoprecipitated chromatin bound by either isotype control (IgG) or p53 (IP) was quantified by real-time PCR with specific 
primers. Specific signals were set relative to signals obtained for the imput chromatin. One representative experiment of 3 
indipendent ChIP is shown. p value, compared with normalized (IP/IgG) DMSO and Nutlin-3a-treated LA-N-5 (two-tailed paired 
Student’s t-test). *p<0.05. 
 
All these data suggest that a Nutlin-3a pharmacological treatment aimed to improve the 
expression of ligands for NK cell-activating receptor, could represent a novel promising 
therapeutic strategy to restore the NK cell-mediated immune response against high-risk NB cells. 
 
Nutlin-3a upregulates in vivo the expression of PVR and Nectin-2 in NB cell line grown in 
xenograft murine model. 
 
Based on the in vitro studies, in order to evaluate the efficacy of Nutlin-3a also in vivo, we 
performed in vivo experiments in xenograft murine model. MYCN-amplified LA-N-5 cells were 
injected subcutaneously into NSG mice, and tumours thereby generated were treated 
intraperitonealy (i.p) with Nutlin-3 (or vehicle as control) at the doses of 20 mg/kg and 40mg/kg 
for two weeks. Mice were sacrificed at the end of treatment and tumour masses were harvested. 
Tissue sections of LA-N-5 xenografts from NSG mice treated with control DMSO or Nutlin-3a
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were stained with PVR and Nectin-2 antibodies. Immunohistochemistry assay showed a 
significant increased expression of both PVR and Nectin2 ligands, in slides from treated 
compared with untreated mice (Fig. 31). 
 
Fig.31 (A) Immunohistochemical staining of LA-N-5 xenograft using PVR and Nectin-2 antibodies. LA-N-5 xenografts were 
treated intraperitoneally with DMSO or Nutlin-3a at 20mg/kg (drug dose/mouse body weight) and at 40mg/kg indicated doses 
every two days for two weeks. Groups of five NSG mice for each condition were assessed. Mice were sacrificed at the end of 
Nutlin-3a treatment and tumour masses were harvested, formaldehyde-fixed, thus paraffin-embedded blocks were cut into 3-mm 
sections. Tissues slides from DMSO, Nutlin-3a at 20mg/kg and at 40mg/kg masses were mounted on the same slide and parallel 
stained for the same antibody. A representative out of six independent slides for each condition is shown. (B) 
Immunohistochemical staining was measured by ImageJ software and the mean+SD of integrated density of ten independent 
areas on four independent slides for each condition are reported in histogram. p value, compared with DMSO and Nutlin-3a- 
treated mice (two-tailed paired Student’s t-test). *p<0.05, **p<0.01. 
 
 
NK cells combined with Nutlin-3a treatment improve the overall survival of MYCN- 
amplified NB cell-bearing mice (ongoing assay). 
 
Next, we asked if the increased expression of ligands for NK cell-activating receptors mediated 
by Nutlin-3a treatment, may improve NK cell activity in impairing tumour growth. NSG mice 
injected subcutaneously into the right flank with LA-N-5 NB cell line were divided into 4 groups: 
1) injected with vehicles, 2) i.p treated with Nutlin-3a (40mg/kg), 3) intravenously (i.v.) treated 
with NK cells and 4) i.p. treated with Nutlin-3a plus i.v. treated with NK cells. We have
preliminary results showing that the combined treatment of Nutlin-3a with NK cells could 
significantly improve mice overall survival (data not shown). Altogether, these results 
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demonstrate that in vivo treatment of MYCN-amplified NB with Nutlin- 3a and NK cells, affects 
tumour growth. 
 
Nutlin-3a render NB primary cells more susceptible to NK cell-mediated recognition and 
lysis by improving the expression of some ligands for NK cell-activating receptors. 
 
Since we demonstrated a significant up-modulation of ULBP1, ULBP2/5/6, ULBP3 and PVR 
ligands in NB cell line after Nutlin-3a treatment, we explored Nutlin-3a effect also on primary 
NB samples isolated by NB patients characterized by different stage of the disease. Therefore, 
NB primary cells treated with 2µM of Nutlin-3a for 48h showed an up-regulation of some ligands 
for NK cell-activating receptors with different results among NB primary cells (data not shown). 
Primary cells obtained by one patient with high-risk NB, characterized by MYCN-amplification, 
spontaneously developed in culture spheroids. To examine the NK cell ability to attack these 
spheroids, we performed a co-cultured of NK cells and Nutlin-3a pre-treated NB spheroids at the 
ratio E:T of 1:1. Then, we acquired images by optical microscopy and measured by Image J the 
major diameter of spheroids at 0 and 4h after NK cell adding. The diameter of spheroids increased 
under NK cell attack as the result of NK cell-mediated disaggregation. As shown in Fig. 32, 
Nutlin-3a was able to render significantly more susceptible spheroids to NK cells attack. These 
data were confirmed also by apoptotic analysis of spheroids upon NK cell exposition. 
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Fig. 32 Primary NB spheroids are recognized and destroyed by NK cells. Optical Microscopy acquisition and ImageJ analysis 
of the major diameter of spheroids of primary NB samples spontaneously developed in vitro isolated by a patient with high-risk 
NB upon in vitro NK cell attack. Apoptotic state was measured by Annexin V/PI staining. 
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Discussion 
 
The antitumor activity of NK cells is strictly dependent on the expression of ligands for NK cell- 
activating receptors on tumour cell surfaces [156, 167]. The down-modulation of such ligands 
represent one of the mechanisms of immune-evasion for many tumours, including NB [168]. The 
up-regulation of activating ligands represent efficient strategies aimed to boost the NK cell-based 
anti-tumour immunotherapy. 
MYCN oncogene represents the well-established predictor of poor prognosis in high-risk NB and 
it is known to be an important transcriptional factor able to confer metastatic and immune- 
evasion capabilities and to regulate several cellular processes such as survival, differentiation and 
apoptosis [8, 20]. MYCN expression in NB cells is positively correlated with that of p53 and 
inversely with that of c-MYC [27], in agreement with the finding that both transcription factors 
are involved in the induction of ULBPs ligands [120]. p53 is mutated in 2% of the cases of NB, 
especially in relapse [13]. The function of p53 protein is inhibited by the MDM2, which is 
overexpressed in many human cancers, including NB [157]. Of note, p53 and MDM2 genes are 
both direct transcriptional targets of MYCN in NB. Consequently, there are many experimental 
evidences suggesting a direct or indirect involvement of MYCN in the modulation of these 
surface activating ligands. 
Based on these observations, we hypothesize that the inverse correlation between the expression 
of MYCN and that of c-MYC or the p53 functional status could explain differences in expression 
of ULBPs ligands in NB cell lines. Our data demonstrate that MYCN has an immunosuppressive 
role dampening the expression of ligands for NK cell-activating receptors and its overexpression 
contributes to protect NB cells from NK cell-mediated recognition and killing, thus delineating 
a novel mechanism of tumour escape from the control of the innate immune system. Our study 
shows that the expression of MYCN is inversely correlated with that of the activating ligands for 
NKG2D and DNAM-1 NK-cell receptors in NB cells. Moreover, since higher levels of soluble 
MICA have been reported to be found in sera of NB patients compared with healthy donors [168], 
the putative role of MYCN in regulating cell surface expression of activating ligands by non- 
transcriptional mechanisms cannot be excluded and needs further investigation. As a 
consequence, MYCN expression could represent a biomarker allowing to predict the 
susceptibility of NB cells to NK cell-mediated immunotherapy. 
MYCN targeting could be a therapeutic strategy to induce the expression of activating ligands 
and enhance NB cell susceptibility to NK cell-mediated immunotherapy. Among several 
mechanisms leading, the BET bromodomain inhibitor JQ1 is a good candidate to down-regulate 
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MYCN expression/function. The use of JQ1 is very promising in several c-MYC- amplified 
tumours in which the downregulation of c-MYC leads to cell cycle arrest and apoptosis [161, 169]. 
Moreover, JQ1 showed anti-angiogenesis activity contributing to arrest of the growth of paediatric 
sarcoma [170]. JQ1 also dampens the expression of PD-L1, a major player involved in immune 
checkpoint mechanisms in NB and in other cancers [171, 172]. These data indicate that JQ1 
treatment could represent a good strategy enhancing a better lymphocyte-mediated recognition 
of NB cells by reducing the PD1/PD-L1 immune checkpoint pathway established between 
lymphocytes and NB cells. Moreover, JQ1 increased the expression of MICA in multiple 
myeloma, since the downregulation of c-MYC leads to up-modulation of miR-125-5p and the 
consequent downregulation of its target gene IRF4, known as transcription repressor of MICA 
[173]. Differently to haematological malignancies, solid tumours, including NB, express lower 
levels of MICA and MICB and higher levels of ULBPs and ligands for DNAM-1 [125]. 
Moreover, the shedding of MICA has been associated with an immune escape strategy of NB 
[168]. 
Our data showed that JQ1, although efficiently down-modulates the expression of MYCN and 
strongly reduced the level of reactive oxygen species (ROS), rendered NB cell lines more resistant 
to NK cells and probably also to T cells (not explored here), due to the shared expression of 
NKG2D on these lymphocytes. In spite of the cytotoxic activity of JQ1 against NB cells, the 
inability of the drug to up-regulate the expression of activating ligands, with consequent 
resistance of NB cells to NK cell-mediated attack, should discourage the use of JQ1 in 
combination with the perspective NK cell-based immunotherapy of NB. 
For this reason, we focused our attention on the use of drugs able to stimulate p53 that, together 
with c-MYC, is known to regulate NK cell-activating receptor ligands such as ULBP1, ULBP2. 
Several are the drug-mediated molecular mechanisms underlying the up-regulation of activating 
ligands, representing efficient strategies aimed to boost the NK cell-based anti-tumour 
immunotherapy [174]. Stress induced by drugs up-regulate the expression of ligands for NKG2D 
and DNAM-1 activating receptors, by activating ATM (ataxia telangiectasia mutated) and ATR 
(ATM- and Rad3-related) protein kinases [49]. The ATM/ATR pathways are under control of 
two main checkpoint kinases, that are Chk1 and Chk2 and, through the activation of the master 
transcription factor p53, lead to cell senescence and induce the expression of ligands for NK cell- 
activating receptors [34]. In order to evaluate whether drugs commonly use in high-risk NB 
treatment (cisplatin, etoposide, irinotecan, and topotecan) could sustain the NK cell-mediated 
antitumor function, we studied the expression of ligands for NK cell-activating receptors on a 
panel of NB cell lines. No drugs showed a significant immune adjuvant effect confirmed also by 
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an NK cell functional assay upon cisplatin treatment. This refractoriness was partially related to 
the abnormal status of ATM, ATR, CHEK1, and CHEK2 genes in the NB cell lines tested. Of 
note, ATM deletion correlates with lower event-free survival and overall survival in patients 
affected by NB, independently of MYCN amplification. The altered ATM/ATR induction in NB 
cells could inhibit the effect mediated by many genotoxic drugs in terms of the induced 
expression of ligands for NK cell-activating receptors. Moreover, our data showed that both the 
impaired production of ROS in some NB cell lines and the transient p53 stabilization after drug 
treatment at pre-apoptotic concentrations could contribute to inefficient induction of NKG2D and 
DNAM-1 ligands. It cannot be excluded that in our drug treatment conditions the apoptosis 
induced at 48h and at higher doses could depend also on p53-independent mechanisms occurring 
in NB, as reported by other authors [175] [176]. 
A way to bypass ATM-ATR pathway is to directly target p53. It is known that the 
p53/MDM2/p14(ARF) pathway is often inactivated through MDM2 amplification or p14(ARF) 
inactivation. Nutlins were the first potent and selective inhibitors of the MDM2–p53 interaction 
[57], in particular Nutlin-3a was evaluated both in vitro and in vivo in several types of human 
cancers, also NB [158]. MDM2–p53 antagonists have been shown to activate the p53 pathway, 
triggering p53-dependent cell cycle arrest and/or apoptosis, while inducing a reversible cell cycle 
arrest in normal cells [177]. Several studies showed that Nutlin-3a is less toxic to normal cells 
than to neoplastic cells [135]. Moreover, Nutlin-3a can induce a cellular senescence [136]. 
We show p53 restoration activity by Nutlin-3a therapy can strongly potentiate the ULBP1, 
ULBP2/5/6, ULBP3 and PVR activating ligands expression in wt p53 NB cells. Real-time PCR 
and ChIP assays, after Nutlin-3a treatment, revealed an increased transcription of PVR mRNA 
due to a direct p53 binding on PVR promoter. Nutlin-3a makes MYCN-amplified NB cell lines, 
more susceptible to NK cell-mediated recognition and lysis: despite amplification of MDM2 is 
common in MYCN amplified cell lines, nutlin-3 therapy effectively overcomes the p53 inhibition 
imposed by excess levels of MDM2. Moreover, in vivo experiments performed in xenograft NSG 
mice model and immunohistochemestry analysis, demonstrate the efficacy of Nutlin-3a in 
inducing the ligands for DNAM-1 NK cell activating receptor. 
NK cells are a fundamental component of the innate immune system, capable of recognizing and 
destroying tumour cells, and they play an important role in adaptive immunity by modulating 
dendritic cell function as well as controlling antigen-specific T cell responses. Therapies 
involving NK cells may activate endogenous NK cells or involve transfer of exogenous cells by 
hematopoietic stem cell transplantation (HSCT) or adoptive cell therapy. 
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Presently, the in vivo adoptive transfer of mature in vitro activated and expanded NK cells, in 
autologous or allogeneic settings, represents a promising approach to treat NB. Nowadays, there 
are different clinical trials based on the use of mature NK cells combined with some therapeutic 
agents, such as anti-GD2 (ch14.18/CHO) (http://ClinicalTrials.gov). 
We treated NB bearing NSG mice with a combined treatment of mature NK cell expanded from 
healthy donor and Nutlin-3a and we observed a better overall survival of mice that received a 
combined treatment compared with mice that received only NK cell treatment. This data suggests 
Nutlin-3a as a new therapeutic approach to potentiate the function of adoptively transfer NK 
cells, in autologous or allogenic setting, as a new NK cell-based immunotherapy of NB. 
In conclusion we can assert that MYCN overexpression contributes to protect NB cells from NK- 
cell-mediated recognition and killing, delineating a novel mechanism of tumour escape from the 
control of the innate immune system. In this context, restoring the p53 transcription factors level 
and function, through Nutlin-3a use, could pave the way for a promising approaches able to 
stimulate the activating ligand expression on high-risk NB cells and potentiate the NK cell- 
mediated cytotoxicity and killing. 
Further investigations in vivo are warranted to better understand the complex mechanisms 
involved in NK cell-mediated killing in order to design a translational approach for cancer 
immunotherapy. 
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